DDI-MedLine.d78.s1	The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
fluoroquinolones	group	4-19	antibiotics	group	52-62	false

DDI-MedLine.d78.s2	These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	24-34	ciprofloxacin	drug	37-49	false
norfloxacin	drug	24-34	ofloxacin	drug	52-60	false
norfloxacin	drug	24-34	enoxacin	drug	63-70	false
norfloxacin	drug	24-34	lomefloxacin	drug	77-88	false
ciprofloxacin	drug	37-49	ofloxacin	drug	52-60	false
ciprofloxacin	drug	37-49	enoxacin	drug	63-70	false
ciprofloxacin	drug	37-49	lomefloxacin	drug	77-88	false
ofloxacin	drug	52-60	enoxacin	drug	63-70	false
ofloxacin	drug	52-60	lomefloxacin	drug	77-88	false
enoxacin	drug	63-70	lomefloxacin	drug	77-88	false

DDI-MedLine.d78.s3	Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used.
antibiotics	group	36-46	antibiotics	drug	180-190	false

DDI-MedLine.d80.s1	In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	group	79-112	POC	group	115-117	false
progestin-only oral contraceptives	group	79-112	norgestrel	drug	166-175	false
progestin-only oral contraceptives	group	79-112	norethindrone	drug	192-204	false
POC	group	115-117	norgestrel	drug	166-175	false
POC	group	115-117	norethindrone	drug	192-204	false
norgestrel	drug	166-175	norethindrone	drug	192-204	false

DDI-MedLine.d84.s0	Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
Ganoderma lucidum extract	drug_n	26-50	antibiotics	group	87-97	false

DDI-MedLine.d84.s3	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	60-61	antibiotics	group	82-92	false
GL	drug_n	60-61	ampicillin	drug	95-104	false
GL	drug_n	60-61	cefazolin	drug	107-115	false
GL	drug_n	60-61	oxytetracycline	drug	118-132	false
GL	drug_n	60-61	chloramphenicol	drug	138-152	false
antibiotics	group	82-92	ampicillin	drug	95-104	false
antibiotics	group	82-92	cefazolin	drug	107-115	false
antibiotics	group	82-92	oxytetracycline	drug	118-132	false
antibiotics	group	82-92	chloramphenicol	drug	138-152	false
ampicillin	drug	95-104	cefazolin	drug	107-115	false
ampicillin	drug	95-104	oxytetracycline	drug	118-132	false
ampicillin	drug	95-104	chloramphenicol	drug	138-152	false
cefazolin	drug	107-115	oxytetracycline	drug	118-132	false
cefazolin	drug	107-115	chloramphenicol	drug	138-152	false
oxytetracycline	drug	118-132	chloramphenicol	drug	138-152	false

DDI-MedLine.d84.s4	The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
GL	drug_n	34-35	antibiotics	group	47-57	true

DDI-MedLine.d84.s5	Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
GL	drug_n	28-29	cefazolin	drug	49-57	true

DDI-MedLine.d13.s7	On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts.
amphetamine	drug	69-79	heroin	drug_n	247-252	false

DDI-MedLine.d13.s8	However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.
alcohol	drug	32-38	amphetamine	drug	99-109	false
alcohol	drug	32-38	heroin	drug_n	114-119	false
amphetamine	drug	99-109	heroin	drug_n	114-119	false

DDI-MedLine.d69.s0	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.
contortrostatin	drug_n	70-84	echistatin	drug_n	141-150	false
contortrostatin	drug_n	70-84	flavoridin	drug_n	156-165	false
echistatin	drug_n	141-150	flavoridin	drug_n	156-165	false

DDI-MedLine.d69.s1	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
contortrostatin	drug_n	28-42	echistatin	drug_n	96-105	false
contortrostatin	drug_n	28-42	flavoridin	drug_n	111-120	false
echistatin	drug_n	96-105	flavoridin	drug_n	111-120	false

DDI-MedLine.d69.s3	Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
Echistatin	drug_n	0-9	contortrostatin	drug_n	118-132	true

DDI-MedLine.d69.s5	Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
Flavoridin	drug_n	0-9	contortrostatin	drug_n	78-92	true

DDI-MedLine.d48.s3	Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A.
Diethyl pyrocarbonate	drug_n	0-20	toxin A	drug_n	94-100	false

DDI-MedLine.d48.s4	Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
toxin A	drug_n	16-22	diethyl pyrocarbonate	drug_n	29-49	false

DDI-MedLine.d48.s5	Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules.
toxin A	drug_n	13-19	diethyl pyrocarbonate	drug_n	34-54	false

DDI-MedLine.d48.s6	The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment.
diethyl pyrocarbonate	drug_n	15-35	hydroxylamine	drug_n	58-70	false

DDI-MedLine.d48.s11	Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.
toxin A	drug_n	22-28	zinc	drug	48-51	false
toxin A	drug_n	22-28	toxin A	drug_n	150-156	false
toxin A	drug_n	22-28	zinc	drug	164-167	false
zinc	drug	48-51	toxin A	drug_n	150-156	false
zinc	drug	48-51	zinc	drug	164-167	false
toxin A	drug_n	150-156	zinc	drug	164-167	false

DDI-MedLine.d18.s0	Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
budesonide	drug	42-51	Survanta	brand	56-63	false
budesonide	drug	42-51	lung surfactant	group	74-88	false
Survanta	brand	56-63	lung surfactant	group	74-88	false

DDI-MedLine.d18.s1	The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined.
pulmonary surfactant	group	16-35	Survanta	brand	63-70	false
pulmonary surfactant	group	16-35	budesonide	drug	121-130	false
Survanta	brand	63-70	budesonide	drug	121-130	false

DDI-MedLine.d18.s2	Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.
budesonide	drug	21-30	ethanol	drug	55-61	false

DDI-MedLine.d18.s6	Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies.
Survanta	brand	0-7	budesonide	drug	48-57	false

DDI-MedLine.d18.s7	Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate.
Survanta	brand	0-7	sodium dodecyl sulfate	drug_n	68-89	false

DDI-MedLine.d18.s8	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
budesonide	drug	33-42	budesonide	drug	121-130	false
budesonide	drug	33-42	Survanta	brand	144-151	false
budesonide	drug	121-130	Survanta	brand	144-151	false

DDI-MedLine.d62.s1	As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects.
methamphetamine	drug	141-155	METH	drug	158-161	false

DDI-MedLine.d62.s4	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
METH	drug	46-49	SCH-23390	drug_n	234-242	true
METH	drug	46-49	atypical neuroleptic	group	258-277	false
METH	drug	46-49	clozapine	drug	279-287	false
SCH-23390	drug_n	234-242	atypical neuroleptic	group	258-277	false
SCH-23390	drug_n	234-242	clozapine	drug	279-287	false
atypical neuroleptic	group	258-277	clozapine	drug	279-287	false

DDI-MedLine.d104.s0	The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
DCG-IV	drug_n	15-20	L-CCG-1	drug_n	26-32	false
DCG-IV	drug_n	15-20	phencyclidine	drug_n	39-51	false
DCG-IV	drug_n	15-20	PCP	drug_n	54-56	false
L-CCG-1	drug_n	26-32	phencyclidine	drug_n	39-51	false
L-CCG-1	drug_n	26-32	PCP	drug_n	54-56	false
phencyclidine	drug_n	39-51	PCP	drug_n	54-56	false

DDI-MedLine.d104.s2	injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior.
phencyclidine	drug_n	13-25	PCP	drug_n	28-30	false

DDI-MedLine.d104.s3	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found.
DCG-IV	drug_n	71-76	L-CCG-1	drug_n	82-88	false
DCG-IV	drug_n	71-76	PCP	drug_n	134-136	false
L-CCG-1	drug_n	82-88	PCP	drug_n	134-136	false

DDI-MedLine.d104.s4	The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
DCG-IV	drug_n	15-20	PCP	drug_n	68-70	true

DDI-MedLine.d104.s8	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.
PCP	drug_n	49-51	PCP	drug_n	171-173	false
PCP	drug_n	171-173	DCG-IV	drug_n	176-181	false
PCP	drug_n	171-173	L-CCG-1	drug_n	188-194	false
DCG-IV	drug_n	176-181	L-CCG-1	drug_n	188-194	false

DDI-MedLine.d98.s0	Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
cocaine	drug	33-39	pentobarbital	drug	107-119	false

DDI-MedLine.d98.s1	Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization.
pentobarbital	drug	82-94	cocaine	drug	225-231	false

DDI-MedLine.d110.s0	18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-Methoxycoronaridine	drug_n	0-21	18-MC	drug_n	24-28	false
18-Methoxycoronaridine	drug_n	0-21	ibogaine	drug_n	35-42	false
18-MC	drug_n	24-28	ibogaine	drug_n	35-42	false

DDI-MedLine.d110.s2	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;
ibogaine	drug_n	5-12	18-MC	drug_n	26-30	false
ibogaine	drug_n	5-12	morphine	drug	92-99	false
ibogaine	drug_n	5-12	cocaine	drug	105-111	false
ibogaine	drug_n	5-12	ethanol	drug	149-155	false
ibogaine	drug_n	5-12	nicotine	drug	161-168	false
18-MC	drug_n	26-30	morphine	drug	92-99	false
18-MC	drug_n	26-30	cocaine	drug	105-111	false
18-MC	drug_n	26-30	ethanol	drug	149-155	false
18-MC	drug_n	26-30	nicotine	drug	161-168	false
morphine	drug	92-99	cocaine	drug	105-111	false
morphine	drug	92-99	ethanol	drug	149-155	false
morphine	drug	92-99	nicotine	drug	161-168	false
cocaine	drug	105-111	ethanol	drug	149-155	false
cocaine	drug	105-111	nicotine	drug	161-168	false
ethanol	drug	149-155	nicotine	drug	161-168	false

DDI-MedLine.d110.s3	unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water).
ibogaine	drug_n	7-14	18-MC	drug_n	17-21	false

DDI-MedLine.d110.s4	Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	opioid	group	35-40	false
18-MC	drug_n	18-22	opioid	group	35-40	false

DDI-MedLine.d110.s5	Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	ibogaine	drug_n	101-108	false
18-MC	drug_n	18-22	ibogaine	drug_n	101-108	false

DDI-MedLine.d110.s6	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	morphine	drug	30-37	true
ibogaine	drug_n	5-12	nicotine	drug	51-58	true
18-MC	drug_n	18-22	morphine	drug	30-37	true
18-MC	drug_n	18-22	nicotine	drug	51-58	true
morphine	drug	30-37	nicotine	drug	51-58	false

DDI-MedLine.d110.s7	only ibogaine enhances cocaine-induced increases in accumbal dopamine.
ibogaine	drug_n	5-12	cocaine	drug	23-29	true

DDI-MedLine.d110.s8	Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false

DDI-MedLine.d110.s9	Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
Ibogaine	drug_n	0-7	18-MC	drug_n	25-29	false
Ibogaine	drug_n	0-7	morphine	drug	75-82	true
18-MC	drug_n	25-29	morphine	drug	75-82	true

DDI-MedLine.d110.s10	both compounds attenuate morphine-induced locomotion in morphine-experienced rats.
morphine	drug	25-32	morphine	drug	56-63	false

DDI-MedLine.d110.s13	Ibogaine, but not 18-MC, decreases heart rate at high doses.
Ibogaine	drug_n	0-7	18-MC	drug_n	18-22	false

DDI-MedLine.d110.s14	While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	drug_n	6-10	ibogaine	drug_n	16-23	false
18-MC	drug_n	6-10	18-MC	drug_n	100-104	false
18-MC	drug_n	6-10	ibogaine	drug_n	137-144	false
ibogaine	drug_n	16-23	18-MC	drug_n	100-104	false
ibogaine	drug_n	16-23	ibogaine	drug_n	137-144	false
18-MC	drug_n	100-104	ibogaine	drug_n	137-144	false

DDI-MedLine.d110.s15	Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.
18-MC	drug_n	5-9	ibogaine	drug_n	15-22	false
18-MC	drug_n	5-9	ibogaine	drug_n	57-64	false
18-MC	drug_n	5-9	18-MC	drug_n	67-71	false
ibogaine	drug_n	15-22	ibogaine	drug_n	57-64	false
ibogaine	drug_n	15-22	18-MC	drug_n	67-71	false
ibogaine	drug_n	57-64	18-MC	drug_n	67-71	false

DDI-MedLine.d110.s16	The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.
18-MC	drug_n	22-26	ibogaine	drug_n	124-131	false

DDI-MedLine.d106.s0	Clinical implications of warfarin interactions with five sedatives.
warfarin	drug	25-32	sedatives	group	57-65	true

DDI-MedLine.d106.s1	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
anticoagulant	group	45-57	phenobarbital	drug	75-87	false
anticoagulant	group	45-57	secobarbital	drug	90-101	false
anticoagulant	group	45-57	glutethimide	drug	104-115	false
anticoagulant	group	45-57	chloral hydrate	drug	118-132	false
anticoagulant	group	45-57	methaqualone	drug	138-149	false
anticoagulant	group	45-57	coumarin	group	209-216	false
phenobarbital	drug	75-87	secobarbital	drug	90-101	false
phenobarbital	drug	75-87	glutethimide	drug	104-115	false
phenobarbital	drug	75-87	chloral hydrate	drug	118-132	false
phenobarbital	drug	75-87	methaqualone	drug	138-149	false
phenobarbital	drug	75-87	coumarin	group	209-216	false
secobarbital	drug	90-101	glutethimide	drug	104-115	false
secobarbital	drug	90-101	chloral hydrate	drug	118-132	false
secobarbital	drug	90-101	methaqualone	drug	138-149	false
secobarbital	drug	90-101	coumarin	group	209-216	false
glutethimide	drug	104-115	chloral hydrate	drug	118-132	false
glutethimide	drug	104-115	methaqualone	drug	138-149	false
glutethimide	drug	104-115	coumarin	group	209-216	false
chloral hydrate	drug	118-132	methaqualone	drug	138-149	false
chloral hydrate	drug	118-132	coumarin	group	209-216	false
methaqualone	drug	138-149	coumarin	group	209-216	false

DDI-MedLine.d106.s4	Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide;
phenobarbital	drug	67-79	secobarbital	drug	82-93	false
phenobarbital	drug	67-79	glutethimide	drug	99-110	false
secobarbital	drug	82-93	glutethimide	drug	99-110	false

DDI-MedLine.d106.s5	there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone.
chloral hydrate	drug	81-95	methaqualone	drug	101-112	false

DDI-MedLine.d106.s6	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
Barbiturates	group	0-11	glutethimide	drug	17-28	false
Barbiturates	group	0-11	coumarin drugs	group	79-92	true
glutethimide	drug	17-28	coumarin drugs	group	79-92	true

DDI-MedLine.d106.s8	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
Chloral hydrate	drug	0-14	methaqualone	drug	20-31	false
Chloral hydrate	drug	0-14	anticoagulant agents	group	85-104	true
methaqualone	drug	20-31	anticoagulant agents	group	85-104	true

DDI-MedLine.d106.s9	It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
chloral hydrate	drug	21-35	methaqualone	drug	41-52	false
chloral hydrate	drug	21-35	anticoagulant	group	151-163	false
methaqualone	drug	41-52	anticoagulant	group	151-163	false

DDI-MedLine.d127.s6	Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin.
thiazide diuretics	group	20-37	digoxin	drug	92-98	false

DDI-MedLine.d135.s0	Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
clozapine	drug	16-24	phencyclidine	drug_n	30-42	false

DDI-MedLine.d135.s1	Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.
Phencyclidine	drug_n	0-12	PCP	drug_n	15-17	false

DDI-MedLine.d135.s3	In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
atypical antipsychotic	group	26-47	clozapine	drug	49-57	false
atypical antipsychotic	group	26-47	PCP	drug_n	108-110	false
clozapine	drug	49-57	PCP	drug_n	108-110	false

DDI-MedLine.d135.s4	PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.
PCP	drug_n	0-2	PCP	drug_n	87-89	false

DDI-MedLine.d135.s5	Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone.
clozapine	drug	18-26	PCP	drug_n	70-72	false

DDI-MedLine.d135.s6	These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
clozapine	drug	45-53	PCP	drug_n	111-113	false

DDI-MedLine.d135.s8	Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.
antipsychotics	group	61-74	PCP	drug_n	183-185	false

DDI-MedLine.d95.s4	Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
Resveratrol	drug_n	0-10	noradrenaline	drug	116-128	false
Resveratrol	drug_n	0-10	KCl	drug	148-150	false
noradrenaline	drug	116-128	KCl	drug	148-150	false

DDI-MedLine.d95.s6	However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves.
L-NAME	drug_n	9-14	reseveratrol	drug_n	70-81	false

DDI-MedLine.d95.s7	Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats.
Indomethacin	drug	0-11	resveratrol	drug_n	46-56	false

DDI-MedLine.d95.s8	In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium.
noradrenaline	drug	3-15	resveratrol	drug_n	78-88	false

DDI-MedLine.d95.s9	This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.
resveratrol	drug_n	54-64	resveratrol	drug_n	190-200	false

DDI-MedLine.d79.s0	If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
indinavir	drug	23-31	IDV	drug	34-36	false
indinavir	drug	23-31	didanosine	drug	40-49	false
indinavir	drug	23-31	IDV	drug	67-69	false
IDV	drug	34-36	didanosine	drug	40-49	false
IDV	drug	34-36	IDV	drug	67-69	false
didanosine	drug	40-49	IDV	drug	67-69	false

DDI-MedLine.d79.s1	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
indinavir	drug	29-37	didanosine	drug	43-52	true
indinavir	drug	29-37	indinavir	drug	101-109	false
indinavir	drug	29-37	didanosine	drug	145-154	false
indinavir	drug	29-37	indinavir	drug	171-179	false
didanosine	drug	43-52	indinavir	drug	101-109	false
didanosine	drug	43-52	didanosine	drug	145-154	false
didanosine	drug	43-52	indinavir	drug	171-179	false
indinavir	drug	101-109	didanosine	drug	145-154	false
indinavir	drug	101-109	indinavir	drug	171-179	false
didanosine	drug	145-154	indinavir	drug	171-179	false

DDI-MedLine.d79.s2	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration.
indinavir	drug	12-20	indinavir	drug	127-135	false
indinavir	drug	12-20	indinavir	drug	160-168	false
indinavir	drug	12-20	didanosine	drug	193-202	false
indinavir	drug	127-135	indinavir	drug	160-168	false
indinavir	drug	127-135	didanosine	drug	193-202	false
indinavir	drug	160-168	didanosine	drug	193-202	false

DDI-MedLine.d79.s3	Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
indinavir	drug	48-56	didanosine	drug	74-83	true

DDI-MedLine.d79.s5	Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
Indinavir	drug	0-8	didanosine	drug	87-96	true

DDI-MedLine.d59.s4	Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
Cytochalasin D	drug_n	0-13	carbachol	drug	75-83	true

DDI-MedLine.d59.s5	Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
Cytochalasin D	drug_n	0-13	carbachol	drug	29-37	true

DDI-MedLine.d75.s3	The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not <
mu-selective opioids	group	44-46;70-86	delta(1)-selective opioids	group	49-57;70-86	false
mu-selective opioids	group	44-46;70-86	kappa-selective opioids	group	64-86	false
delta(1)-selective opioids	group	49-57;70-86	kappa-selective opioids	group	64-86	false

DDI-MedLine.d133.s0	Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
verapamil	drug	15-23	bombesin	drug_n	28-35	true
verapamil	drug	15-23	azoxymethane	drug_n	109-120	false
bombesin	drug_n	28-35	azoxymethane	drug_n	109-120	false

DDI-MedLine.d133.s1	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	54-61	verapamil hydrochloride	drug	67-89	false
bombesin	drug_n	54-61	verapamil	drug	92-100	false
bombesin	drug_n	54-61	calcium channel blocker	group	106-128	false
bombesin	drug_n	54-61	azoxymethane	drug_n	214-225	false
bombesin	drug_n	54-61	AOM	drug_n	228-230	false
verapamil hydrochloride	drug	67-89	verapamil	drug	92-100	false
verapamil hydrochloride	drug	67-89	calcium channel blocker	group	106-128	false
verapamil hydrochloride	drug	67-89	azoxymethane	drug_n	214-225	false
verapamil hydrochloride	drug	67-89	AOM	drug_n	228-230	false
verapamil	drug	92-100	calcium channel blocker	group	106-128	false
verapamil	drug	92-100	azoxymethane	drug_n	214-225	false
verapamil	drug	92-100	AOM	drug_n	228-230	false
calcium channel blocker	group	106-128	azoxymethane	drug_n	214-225	false
calcium channel blocker	group	106-128	AOM	drug_n	228-230	false
azoxymethane	drug_n	214-225	AOM	drug_n	228-230	false

DDI-MedLine.d133.s2	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
AOM	drug_n	100-102	bombesin	drug_n	159-166	false
AOM	drug_n	100-102	verapamil	drug	260-268	false
bombesin	drug_n	159-166	verapamil	drug	260-268	false

DDI-MedLine.d133.s4	Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
verapamil	drug	9-17	bombesin	drug_n	122-129	false

DDI-MedLine.d133.s5	Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
Verapamil	drug	0-8	bombesin	drug_n	117-124	true

DDI-MedLine.d17.s0	In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
prostaglandin F2alpha	drug	24-44	oxytocin	drug	50-57	true

DDI-MedLine.d17.s1	The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro.
prostaglandin F2alpha	drug	19-39	oxytocin	drug	55-62	false

DDI-MedLine.d17.s3	In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha.
norepinephrine	drug	34-47	oxytocin	drug	53-60	false
norepinephrine	drug	34-47	PGF2alpha	drug	67-75	false
oxytocin	drug	53-60	PGF2alpha	drug	67-75	false

DDI-MedLine.d17.s4	PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
PGF2alpha	drug	0-8	oxytocin	drug	93-100	true

DDI-MedLine.d17.s9	There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
PGF2alpha	drug	39-47	oxytocin	drug	91-98	true

DDI-MedLine.d36.s0	Carbamazepine overdose recognized by a tricyclic antidepressant assay.
Carbamazepine	drug	0-12	tricyclic antidepressant	group	39-62	false

DDI-MedLine.d36.s2	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
carbamazepine	drug	73-85	tricyclic antidepressant	group	112-135	true
carbamazepine	drug	73-85	carbamazepine	drug	190-202	false
carbamazepine	drug	73-85	tricyclic antidepressants	group	233-257	false
tricyclic antidepressant	group	112-135	carbamazepine	drug	190-202	false
tricyclic antidepressant	group	112-135	tricyclic antidepressants	group	233-257	false
carbamazepine	drug	190-202	tricyclic antidepressants	group	233-257	true

DDI-MedLine.d126.s0	Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
Cypermethrin	drug	0-11	vitamin E	drug	77-85	true
Cypermethrin	drug	0-11	allopurinol	drug	90-100	true
vitamin E	drug	77-85	allopurinol	drug	90-100	false

DDI-MedLine.d126.s1	Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid.
cypermethrin	drug	213-224	Type II pyrethroid	drug_n	229-246	false

DDI-MedLine.d126.s6	Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
allopurinol	drug	26-36	Vitamin E	drug	57-65	false
allopurinol	drug	26-36	cypermethrin	drug	280-291	true
Vitamin E	drug	57-65	cypermethrin	drug	280-291	true

DDI-MedLine.d126.s7	Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
cypermethrin	drug	31-42	allopurinol	drug	198-208	true
cypermethrin	drug	31-42	Vitamin E	drug	214-222	true
allopurinol	drug	198-208	Vitamin E	drug	214-222	false

DDI-MedLine.d58.s3	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	44-55	selective Ca(2+) channel blockers	group	129-161	false
ginsenosides	drug_n	44-55	nimodipine	drug	163-172	false
ginsenosides	drug_n	44-55	omega-conotoxin GVIA	drug_n	184-203	false
ginsenosides	drug_n	44-55	omega-agatoxin IVA	drug_n	218-235	false
selective Ca(2+) channel blockers	group	129-161	nimodipine	drug	163-172	false
selective Ca(2+) channel blockers	group	129-161	omega-conotoxin GVIA	drug_n	184-203	false
selective Ca(2+) channel blockers	group	129-161	omega-agatoxin IVA	drug_n	218-235	false
nimodipine	drug	163-172	omega-conotoxin GVIA	drug_n	184-203	false
nimodipine	drug	163-172	omega-agatoxin IVA	drug_n	218-235	false
omega-conotoxin GVIA	drug_n	184-203	omega-agatoxin IVA	drug_n	218-235	false

DDI-MedLine.d58.s6	Nimodipine had no effect on ginsenosides response.
Nimodipine	drug	0-9	ginsenosides	drug_n	28-39	false

DDI-MedLine.d58.s7	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	24-35	omega-conotoxin GVIA	drug_n	135-154	false
ginsenosides	drug_n	24-35	omega-agatoxin IVA	drug_n	187-204	false
ginsenosides	drug_n	24-35	nimodipine	drug	237-246	false
ginsenosides	drug_n	24-35	omega-conotoxin GVIA	drug_n	248-267	false
ginsenosides	drug_n	24-35	omega-agatoxin VIA	drug_n	269-286	false
omega-conotoxin GVIA	drug_n	135-154	omega-agatoxin IVA	drug_n	187-204	false
omega-conotoxin GVIA	drug_n	135-154	nimodipine	drug	237-246	false
omega-conotoxin GVIA	drug_n	135-154	omega-conotoxin GVIA	drug_n	248-267	false
omega-conotoxin GVIA	drug_n	135-154	omega-agatoxin VIA	drug_n	269-286	false
omega-agatoxin IVA	drug_n	187-204	nimodipine	drug	237-246	false
omega-agatoxin IVA	drug_n	187-204	omega-conotoxin GVIA	drug_n	248-267	false
omega-agatoxin IVA	drug_n	187-204	omega-agatoxin VIA	drug_n	269-286	false
nimodipine	drug	237-246	omega-conotoxin GVIA	drug_n	248-267	false
nimodipine	drug	237-246	omega-agatoxin VIA	drug_n	269-286	false
omega-conotoxin GVIA	drug_n	248-267	omega-agatoxin VIA	drug_n	269-286	false

DDI-MedLine.d58.s8	Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.
ginsenosides	drug_n	71-82	ginseng	drug	171-177	false

DDI-MedLine.d8.s0	In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
KRM-1648	drug_n	21-28	ofloxacin	drug	68-76	false

DDI-MedLine.d8.s1	The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
benzoxazinorifamycin	drug_n	30-49	KRM-1648	drug_n	52-59	false
benzoxazinorifamycin	drug_n	30-49	ofloxacin	drug	98-106	false
KRM-1648	drug_n	52-59	ofloxacin	drug	98-106	false

DDI-MedLine.d8.s5	ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively.
rifampicin	drug	74-83	rifabutin	drug	89-97	false

DDI-MedLine.d8.s6	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
ofloxacin	drug	19-27	KRM-1648	drug_n	30-37	true
ofloxacin	drug	19-27	rifampicin	drug	143-152	false
ofloxacin	drug	19-27	rifabutin	drug	158-166	false
ofloxacin	drug	19-27	ofloxacin	drug	173-181	false
KRM-1648	drug_n	30-37	rifampicin	drug	143-152	false
KRM-1648	drug_n	30-37	rifabutin	drug	158-166	false
KRM-1648	drug_n	30-37	ofloxacin	drug	173-181	false
rifampicin	drug	143-152	rifabutin	drug	158-166	false
rifampicin	drug	143-152	ofloxacin	drug	173-181	true
rifabutin	drug	158-166	ofloxacin	drug	173-181	true

DDI-MedLine.d114.s1	The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	drug_n	15-27	RR	drug_n	30-31	false
ruthenium red	drug_n	15-27	inositol 1,4,5-trisphosphate	drug_n	37-64	false
ruthenium red	drug_n	15-27	InsP(3)	drug_n	67-73	false
RR	drug_n	30-31	inositol 1,4,5-trisphosphate	drug_n	37-64	false
RR	drug_n	30-31	InsP(3)	drug_n	67-73	false
inositol 1,4,5-trisphosphate	drug_n	37-64	InsP(3)	drug_n	67-73	false

DDI-MedLine.d114.s3	Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
InsP(3)	drug_n	14-20	RR	drug_n	36-37	true

DDI-MedLine.d114.s4	Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
RR	drug_n	50-51	InsP(3)	drug_n	80-86	true

DDI-MedLine.d114.s6	In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses.
RR	drug_n	57-58	InsP(3)	drug_n	77-83	false

DDI-MedLine.d114.s8	In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.
RR	drug_n	32-33	InsP(3)	drug_n	94-100	false

DDI-MedLine.d109.s0	Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
rofecoxib	drug	10-18	digoxin	drug	47-53	false

DDI-MedLine.d109.s1	The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects.
rofecoxib	drug	75-83	digoxin	drug	129-135	false

DDI-MedLine.d109.s5	Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose.
digoxin	drug	44-50	digoxin	drug	114-120	false

DDI-MedLine.d109.s7	For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
digoxin	drug	4-10	rofecoxib	drug	107-115	false
digoxin	drug	4-10	digoxin	drug	119-125	false
digoxin	drug	4-10	digoxin	drug	137-143	false
rofecoxib	drug	107-115	digoxin	drug	119-125	false
rofecoxib	drug	107-115	digoxin	drug	137-143	false
digoxin	drug	119-125	digoxin	drug	137-143	false

DDI-MedLine.d109.s9	The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.
rofecoxib	drug	68-76	digoxin	drug	80-86	false
rofecoxib	drug	68-76	digoxin	drug	102-108	false
digoxin	drug	80-86	digoxin	drug	102-108	false

DDI-MedLine.d109.s11	The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.
digoxin	drug	61-67	rofecoxib	drug	101-109	false

DDI-MedLine.d109.s13	Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.
Rofecoxib	drug	0-8	digoxin	drug	102-108	false

DDI-MedLine.d115.s0	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	12-27	doxorubicin	drug	30-40	false
cyclophosphamide	drug	12-27	vincristine	drug	43-53	false
cyclophosphamide	drug	12-27	prednisone	drug	60-69	false
cyclophosphamide	drug	12-27	highly active antiretroviral	group	89-116	false
doxorubicin	drug	30-40	vincristine	drug	43-53	false
doxorubicin	drug	30-40	prednisone	drug	60-69	false
doxorubicin	drug	30-40	highly active antiretroviral	group	89-116	false
vincristine	drug	43-53	prednisone	drug	60-69	false
vincristine	drug	43-53	highly active antiretroviral	group	89-116	false
prednisone	drug	60-69	highly active antiretroviral	group	89-116	false

DDI-MedLine.d115.s2	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
cyclophosphamide	drug	244-259	doxorubicin	drug	262-272	false
cyclophosphamide	drug	244-259	vincristine	drug	275-285	false
cyclophosphamide	drug	244-259	prednisone	drug	292-301	false
cyclophosphamide	drug	244-259	cyclophosphamide	drug	440-455	false
cyclophosphamide	drug	244-259	doxorubicin	drug	458-468	false
cyclophosphamide	drug	244-259	teniposide	drug	471-480	false
cyclophosphamide	drug	244-259	prednisone	drug	487-496	false
cyclophosphamide	drug	244-259	vincristine	drug	503-513	false
cyclophosphamide	drug	244-259	bleomycin	drug	520-528	false
cyclophosphamide	drug	244-259	antiretroviral	group	549-562	false
doxorubicin	drug	262-272	vincristine	drug	275-285	false
doxorubicin	drug	262-272	prednisone	drug	292-301	false
doxorubicin	drug	262-272	cyclophosphamide	drug	440-455	false
doxorubicin	drug	262-272	doxorubicin	drug	458-468	false
doxorubicin	drug	262-272	teniposide	drug	471-480	false
doxorubicin	drug	262-272	prednisone	drug	487-496	false
doxorubicin	drug	262-272	vincristine	drug	503-513	false
doxorubicin	drug	262-272	bleomycin	drug	520-528	false
doxorubicin	drug	262-272	antiretroviral	group	549-562	false
vincristine	drug	275-285	prednisone	drug	292-301	false
vincristine	drug	275-285	cyclophosphamide	drug	440-455	false
vincristine	drug	275-285	doxorubicin	drug	458-468	false
vincristine	drug	275-285	teniposide	drug	471-480	false
vincristine	drug	275-285	prednisone	drug	487-496	false
vincristine	drug	275-285	vincristine	drug	503-513	false
vincristine	drug	275-285	bleomycin	drug	520-528	false
vincristine	drug	275-285	antiretroviral	group	549-562	false
prednisone	drug	292-301	cyclophosphamide	drug	440-455	false
prednisone	drug	292-301	doxorubicin	drug	458-468	false
prednisone	drug	292-301	teniposide	drug	471-480	false
prednisone	drug	292-301	prednisone	drug	487-496	false
prednisone	drug	292-301	vincristine	drug	503-513	false
prednisone	drug	292-301	bleomycin	drug	520-528	false
prednisone	drug	292-301	antiretroviral	group	549-562	false
cyclophosphamide	drug	440-455	doxorubicin	drug	458-468	false
cyclophosphamide	drug	440-455	teniposide	drug	471-480	false
cyclophosphamide	drug	440-455	prednisone	drug	487-496	false
cyclophosphamide	drug	440-455	vincristine	drug	503-513	false
cyclophosphamide	drug	440-455	bleomycin	drug	520-528	false
cyclophosphamide	drug	440-455	antiretroviral	group	549-562	false
doxorubicin	drug	458-468	teniposide	drug	471-480	false
doxorubicin	drug	458-468	prednisone	drug	487-496	false
doxorubicin	drug	458-468	vincristine	drug	503-513	false
doxorubicin	drug	458-468	bleomycin	drug	520-528	false
doxorubicin	drug	458-468	antiretroviral	group	549-562	false
teniposide	drug	471-480	prednisone	drug	487-496	false
teniposide	drug	471-480	vincristine	drug	503-513	false
teniposide	drug	471-480	bleomycin	drug	520-528	false
teniposide	drug	471-480	antiretroviral	group	549-562	false
prednisone	drug	487-496	vincristine	drug	503-513	false
prednisone	drug	487-496	bleomycin	drug	520-528	false
prednisone	drug	487-496	antiretroviral	group	549-562	false
vincristine	drug	503-513	bleomycin	drug	520-528	false
vincristine	drug	503-513	antiretroviral	group	549-562	false
bleomycin	drug	520-528	antiretroviral	group	549-562	false

DDI-MedLine.d115.s5	Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor.
Antiretroviral	group	0-13	reverse transcriptase inhibitors	group	41-72	false
Antiretroviral	group	0-13	protease inhibitor	group	82-99	false
reverse transcriptase inhibitors	group	41-72	protease inhibitor	group	82-99	false

DDI-MedLine.d115.s14	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
antiretroviral drugs	group	112-125;146-150	antineoplastic drugs	group	131-150	true

DDI-MedLine.d21.s2	Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
antidepressant drugs	group	15-34	hypoglycemic agents	group	106-124	true

DDI-MedLine.d21.s6	Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.
Imipramine	drug	0-9	moclobemide	drug	22-32	false
Imipramine	drug	0-9	clonazepam	drug	46-55	false
Imipramine	drug	0-9	fluoxetine	drug	71-80	false
Imipramine	drug	0-9	sertraline	drug	93-102	false
moclobemide	drug	22-32	clonazepam	drug	46-55	false
moclobemide	drug	22-32	fluoxetine	drug	71-80	false
moclobemide	drug	22-32	sertraline	drug	93-102	false
clonazepam	drug	46-55	fluoxetine	drug	71-80	false
clonazepam	drug	46-55	sertraline	drug	93-102	false
fluoxetine	drug	71-80	sertraline	drug	93-102	false

DDI-MedLine.d21.s8	An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min.
glucose	drug	8-14	glucose	drug	42-48	false

DDI-MedLine.d21.s9	Imipramine and clonazepam did not change fasting or overload glycemia.
Imipramine	drug	0-9	clonazepam	drug	15-24	false

DDI-MedLine.d21.s10	Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
Fluoxetine	drug	0-9	moclobemide	drug	15-25	false
Fluoxetine	drug	0-9	glucose	drug	43-49	false
moclobemide	drug	15-25	glucose	drug	43-49	false

DDI-MedLine.d21.s11	Sertraline neutralized the increase of glycemia induced by oral glucose overload.
Sertraline	drug	0-9	glucose	drug	64-70	false

DDI-MedLine.d21.s12	In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload.
glucose	drug	149-155	glucose	drug	180-186	false

DDI-MedLine.d21.s13	Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats.
sertraline	drug	7-16	glucose	drug	61-67	false

DDI-MedLine.d47.s0	Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
buforin II	drug_n	12-21	azithromycin	drug	53-64	false
buforin II	drug_n	12-21	minocycline	drug	70-80	false
azithromycin	drug	53-64	minocycline	drug	70-80	false

DDI-MedLine.d47.s1	The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated.
buforin II	drug_n	46-55	azithromycin	drug	87-98	false
buforin II	drug_n	46-55	minocycline	drug	104-114	false
azithromycin	drug	87-98	minocycline	drug	104-114	false

DDI-MedLine.d47.s3	Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested.
azithromycin	drug	69-80	minocycline	drug	85-95	false

DDI-MedLine.d47.s4	Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
Buforin II	drug_n	0-9	azithromycin	drug	107-118	true
Buforin II	drug_n	0-9	minocycline	drug	123-133	true
azithromycin	drug	107-118	minocycline	drug	123-133	false

DDI-MedLine.d112.s0	Effect of dofetillide on the pharmacokinetics of digoxin.
dofetillide	drug	10-20	digoxin	drug	49-55	false

DDI-MedLine.d112.s1	The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study.
dofetilide	drug	14-23	digoxin	drug	65-71	false

DDI-MedLine.d112.s2	Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo;
dofetilide	drug	13-22	digoxin	drug	105-111	false

DDI-MedLine.d112.s3	therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.
dofetilide	drug	22-31	digoxin	drug	71-77	false

DDI-MedLine.d19.s4	Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems.
anticonvulsant agents	group	50-70	phenobarbitone	drug	81-94	false
anticonvulsant agents	group	50-70	phenytoin	drug	100-108	false
phenobarbitone	drug	81-94	phenytoin	drug	100-108	false

DDI-MedLine.d16.s0	Interaction of ketamine and halothane in rats.
ketamine	drug	15-22	halothane	drug	28-36	true

DDI-MedLine.d16.s1	The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats.
ketamine	drug	44-51	halothane	drug	107-115	false

DDI-MedLine.d16.s3	However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
halothane	drug	9-17	ketamine	drug	169-176	true

DDI-MedLine.d16.s4	The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1.
ketamine	drug	57-64	ketamine	drug	96-103	false

DDI-MedLine.d16.s5	The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
ketamine	drug	17-24	halothane	drug	76-84	true
ketamine	drug	17-24	ketamine	drug	96-103	false
halothane	drug	76-84	ketamine	drug	96-103	false

DDI-MedLine.d16.s6	It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
ketamine	drug	21-28	halothane	drug	87-95	true

DDI-MedLine.d116.s0	Rifampin and warfarin: a drug interaction.
Rifampin	drug	0-7	warfarin	drug	13-20	true

DDI-MedLine.d116.s1	The drug interaction between warfarin and rifampin is not well known.
warfarin	drug	29-36	rifampin	drug	42-49	true

DDI-MedLine.d116.s2	Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
Rifampin	drug	0-7	warfarin	drug	43-50	true

DDI-MedLine.d116.s3	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
rifampin	drug	34-41	warfarin	drug	47-54	true
rifampin	drug	34-41	warfarin	drug	119-126	false
warfarin	drug	47-54	warfarin	drug	119-126	false

DDI-MedLine.d116.s4	Withdrawal of rifampin decreased the warfarin requirement by 50%.
rifampin	drug	14-21	warfarin	drug	37-44	true

DDI-MedLine.d116.s5	This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
rifampin	drug	46-53	warfarin	drug	113-120	true

DDI-MedLine.d116.s6	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
rifampin	drug	14-21	warfarin	drug	30-37	true
rifampin	drug	14-21	rifampin	drug	125-132	false
rifampin	drug	14-21	rifampin	drug	178-185	false
warfarin	drug	30-37	rifampin	drug	125-132	false
warfarin	drug	30-37	rifampin	drug	178-185	false
rifampin	drug	125-132	rifampin	drug	178-185	false

DDI-MedLine.d76.s1	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
sodium carboxymethylcellulose	drug_n	56-84	NaCMC	drug_n	87-91	false
sodium carboxymethylcellulose	drug_n	56-84	carboxymethylcellulose-cysteine	drug_n	98-128	false
sodium carboxymethylcellulose	drug_n	56-84	CMC-Cys	drug_n	131-137	false
sodium carboxymethylcellulose	drug_n	56-84	sodium fluorescein	drug	183-200	false
sodium carboxymethylcellulose	drug_n	56-84	NaFlu	drug	203-207	false
sodium carboxymethylcellulose	drug_n	56-84	bacitracin	drug	235-244	false
sodium carboxymethylcellulose	drug_n	56-84	insulin	drug	250-256	false
NaCMC	drug_n	87-91	carboxymethylcellulose-cysteine	drug_n	98-128	false
NaCMC	drug_n	87-91	CMC-Cys	drug_n	131-137	false
NaCMC	drug_n	87-91	sodium fluorescein	drug	183-200	false
NaCMC	drug_n	87-91	NaFlu	drug	203-207	false
NaCMC	drug_n	87-91	bacitracin	drug	235-244	false
NaCMC	drug_n	87-91	insulin	drug	250-256	false
carboxymethylcellulose-cysteine	drug_n	98-128	CMC-Cys	drug_n	131-137	false
carboxymethylcellulose-cysteine	drug_n	98-128	sodium fluorescein	drug	183-200	false
carboxymethylcellulose-cysteine	drug_n	98-128	NaFlu	drug	203-207	false
carboxymethylcellulose-cysteine	drug_n	98-128	bacitracin	drug	235-244	false
carboxymethylcellulose-cysteine	drug_n	98-128	insulin	drug	250-256	false
CMC-Cys	drug_n	131-137	sodium fluorescein	drug	183-200	false
CMC-Cys	drug_n	131-137	NaFlu	drug	203-207	false
CMC-Cys	drug_n	131-137	bacitracin	drug	235-244	false
CMC-Cys	drug_n	131-137	insulin	drug	250-256	false
sodium fluorescein	drug	183-200	NaFlu	drug	203-207	false
sodium fluorescein	drug	183-200	bacitracin	drug	235-244	false
sodium fluorescein	drug	183-200	insulin	drug	250-256	false
NaFlu	drug	203-207	bacitracin	drug	235-244	false
NaFlu	drug	203-207	insulin	drug	250-256	false
bacitracin	drug	235-244	insulin	drug	250-256	false

DDI-MedLine.d76.s2	Cysteine was covalently linked to carbodiimide activated NaCMC.
Cysteine	drug	0-7	NaCMC	drug_n	57-61	false

DDI-MedLine.d76.s5	Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
NaCMC	drug_n	11-15	NaFlu	drug	108-112	false
NaCMC	drug_n	11-15	NaCMC	drug_n	134-138	false
NaCMC	drug_n	11-15	cysteine	drug	156-163	false
NaFlu	drug	108-112	NaCMC	drug_n	134-138	false
NaFlu	drug	108-112	cysteine	drug	156-163	false
NaCMC	drug_n	134-138	cysteine	drug	156-163	false

DDI-MedLine.d76.s7	Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2.
CMC-Cys	drug_n	32-38	cysteine	drug	78-85	false
CMC-Cys	drug_n	32-38	NaFlu	drug	153-157	false
cysteine	drug	78-85	NaFlu	drug	153-157	false

DDI-MedLine.d76.s8	NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
NaCMC	drug_n	0-4	cysteine	drug	42-49	false
NaCMC	drug_n	0-4	NaFlu	drug	95-99	false
NaCMC	drug_n	0-4	NaCMC	drug_n	113-117	false
cysteine	drug	42-49	NaFlu	drug	95-99	false
cysteine	drug	42-49	NaCMC	drug_n	113-117	false
NaFlu	drug	95-99	NaCMC	drug_n	113-117	false

DDI-MedLine.d76.s9	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	drug	37-46	insulin	drug	52-58	false
bacitracin	drug	37-46	NaCMC	drug_n	76-80	false
bacitracin	drug	37-46	CMC-Cys	drug_n	173-179	false
insulin	drug	52-58	NaCMC	drug_n	76-80	false
insulin	drug	52-58	CMC-Cys	drug_n	173-179	false
NaCMC	drug_n	76-80	CMC-Cys	drug_n	173-179	false

DDI-MedLine.d76.s10	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	15-19	cysteine	drug	26-33	false
NaCMC	drug_n	15-19	NaFlu	drug	121-125	false
NaCMC	drug_n	15-19	bacitracin	drug	155-164	false
NaCMC	drug_n	15-19	insulin	drug	170-176	false
cysteine	drug	26-33	NaFlu	drug	121-125	false
cysteine	drug	26-33	bacitracin	drug	155-164	false
cysteine	drug	26-33	insulin	drug	170-176	false
NaFlu	drug	121-125	bacitracin	drug	155-164	false
NaFlu	drug	121-125	insulin	drug	170-176	false
bacitracin	drug	155-164	insulin	drug	170-176	false

DDI-MedLine.d3.s0	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
amprenavir	drug	36-45	rifabutin	drug	51-59	false
amprenavir	drug	36-45	rifampin	drug	64-71	false
rifabutin	drug	51-59	rifampin	drug	64-71	false

DDI-MedLine.d3.s1	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
amprenavir	drug	92-101	rifabutin	drug	117-125	false
amprenavir	drug	92-101	rifampin	drug	130-137	false
rifabutin	drug	117-125	rifampin	drug	130-137	false

DDI-MedLine.d3.s3	All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.
amprenavir	drug	22-31	rifabutin	drug	123-131	false
amprenavir	drug	22-31	rifampin	drug	172-179	false
rifabutin	drug	123-131	rifampin	drug	172-179	false

DDI-MedLine.d3.s4	Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.
amprenavir	drug	23-32	rifabutin	drug	39-47	false
amprenavir	drug	23-32	amprenavir	drug	84-93	false
amprenavir	drug	23-32	rifampin	drug	100-107	false
rifabutin	drug	39-47	amprenavir	drug	84-93	false
rifabutin	drug	39-47	rifampin	drug	100-107	false
amprenavir	drug	84-93	rifampin	drug	100-107	false

DDI-MedLine.d3.s5	Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.
amprenavir	drug	51-60	rifabutin	drug	63-71	false
amprenavir	drug	51-60	rifampin	drug	78-85	false
amprenavir	drug	51-60	25-O-desacetyl metabolites	drug_n	97-122	false
rifabutin	drug	63-71	rifampin	drug	78-85	false
rifabutin	drug	63-71	25-O-desacetyl metabolites	drug_n	97-122	false
rifampin	drug	78-85	25-O-desacetyl metabolites	drug_n	97-122	false

DDI-MedLine.d3.s6	Rifabutin did not significantly affect amprenavir's pharmacokinetics.
Rifabutin	drug	0-8	amprenavir	drug	39-48	false

DDI-MedLine.d3.s7	Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
Amprenavir	drug	0-9	rifabutin	drug	89-97	true
Amprenavir	drug	0-9	25-O-desacetylrifabutin	drug_n	131-153	true
rifabutin	drug	89-97	25-O-desacetylrifabutin	drug_n	131-153	false

DDI-MedLine.d3.s8	Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
Rifampin	drug	0-7	amprenavir	drug	48-57	true
Rifampin	drug	0-7	amprenavir	drug	71-80	false
Rifampin	drug	0-7	rifampin	drug	99-106	false
amprenavir	drug	48-57	amprenavir	drug	71-80	false
amprenavir	drug	48-57	rifampin	drug	99-106	false
amprenavir	drug	71-80	rifampin	drug	99-106	false

DDI-MedLine.d3.s10	The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively.
rifabutin	drug	42-50	rifampin	drug	56-63	false

DDI-MedLine.d3.s11	Amprenavir plus rifampin was well tolerated.
Amprenavir	drug	0-9	rifampin	drug	16-23	false

DDI-MedLine.d3.s12	Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
Amprenavir	drug	0-9	rifabutin	drug	16-24	true

DDI-MedLine.d3.s13	Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
Rifampin	drug	0-7	amprenavir	drug	55-64	true

DDI-MedLine.d3.s14	Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
Amprenavir	drug	0-9	rifabutin	drug	48-56	true
Amprenavir	drug	0-9	25-O-desacetylrifabutin	drug_n	62-84	true
rifabutin	drug	48-56	25-O-desacetylrifabutin	drug_n	62-84	false

DDI-MedLine.d3.s15	Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.
Amprenavir	drug	0-9	rifampin	drug	35-42	false
Amprenavir	drug	0-9	rifabutin	drug	48-56	false
rifampin	drug	35-42	rifabutin	drug	48-56	false

DDI-MedLine.d28.s7	The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers"
thiazolidinediones	group	4-21	rosiglitazone	drug	24-36	false
thiazolidinediones	group	4-21	pioglitazone	drug	42-53	false
thiazolidinediones	group	4-21	antidiabetic agents	group	77-95	false
rosiglitazone	drug	24-36	pioglitazone	drug	42-53	false
rosiglitazone	drug	24-36	antidiabetic agents	group	77-95	false
pioglitazone	drug	42-53	antidiabetic agents	group	77-95	false

DDI-MedLine.d74.s2	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
arginine	drug	216-223	glucose	drug	233-239	false
arginine	drug	216-223	theophylline	drug	275-286	false
glucose	drug	233-239	theophylline	drug	275-286	false

DDI-MedLine.d74.s4	Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
Glucose	drug	0-6	theophylline	drug	38-49	false

DDI-MedLine.d74.s5	Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	drug	0-7	glucose	drug	29-35	false
Arginine	drug	0-7	theophylline	drug	41-52	false
glucose	drug	29-35	theophylline	drug	41-52	false

DDI-MedLine.d74.s6	Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	drug	0-7	glucose	drug	28-34	false
Arginine	drug	0-7	theophylline	drug	39-50	false
glucose	drug	28-34	theophylline	drug	39-50	false

DDI-MedLine.d74.s11	Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.
theophylline	drug	108-119	glucose	drug	156-162	false

DDI-MedLine.d44.s2	In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month.
etofibrate	drug	30-39	etofibrate	drug	401-410	false

DDI-MedLine.d44.s6	Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
Etofibrate	drug	0-9	heparin	drug	44-50	true

DDI-MedLine.d125.s0	The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
gliftor	drug_n	42-48	1,3-difluoroacetone	drug_n	69-87	false
gliftor	drug_n	42-48	(-)-erythro-fluorocitrate	drug_n	92-116	false
1,3-difluoroacetone	drug_n	69-87	(-)-erythro-fluorocitrate	drug_n	92-116	false

DDI-MedLine.d125.s1	The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.
1,3-difluoroacetone	drug_n	30-48	Gliftor	drug_n	111-117	false
1,3-difluoroacetone	drug_n	30-48	1,3-difluoro-2-propanol	drug_n	120-142	false
Gliftor	drug_n	111-117	1,3-difluoro-2-propanol	drug_n	120-142	false

DDI-MedLine.d125.s2	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro.
1,3-difluoroacetone	drug_n	91-109	(-)-erythro-fluorocitrate	drug_n	114-138	false

DDI-MedLine.d125.s3	Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.
1,3-difluoroacetone	drug_n	18-36	(-)-erythro-fluorocitrate	drug_n	94-118	false

DDI-MedLine.d125.s4	Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol.
1,3-difluoroacetone	drug_n	19-37	(-)-erythro-fluorocitrate	drug_n	88-112	false
1,3-difluoroacetone	drug_n	19-37	1,3-difluoro-2-propanol	drug_n	201-223	false
(-)-erythro-fluorocitrate	drug_n	88-112	1,3-difluoro-2-propanol	drug_n	201-223	false

DDI-MedLine.d125.s5	We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol.
1,3-difluoro-2-propanol	drug_n	38-60	1,3-difluoroacetone	drug_n	65-83	false
1,3-difluoro-2-propanol	drug_n	38-60	(-)-erythro-fluorocitrate	drug_n	181-205	false
1,3-difluoro-2-propanol	drug_n	38-60	1,3-difluoro-2-propanol	drug_n	212-234	false
1,3-difluoroacetone	drug_n	65-83	(-)-erythro-fluorocitrate	drug_n	181-205	false
1,3-difluoroacetone	drug_n	65-83	1,3-difluoro-2-propanol	drug_n	212-234	false
(-)-erythro-fluorocitrate	drug_n	181-205	1,3-difluoro-2-propanol	drug_n	212-234	false

DDI-MedLine.d125.s6	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
4-methylpyrazole	drug	24-39	1,3-difluoro-2-propanol	drug_n	107-129	true
4-methylpyrazole	drug	24-39	(-)-erythro-fluorocitrate	drug_n	162-186	false
4-methylpyrazole	drug	24-39	1,3-difluoro-2-propanol	drug_n	257-279	false
1,3-difluoro-2-propanol	drug_n	107-129	(-)-erythro-fluorocitrate	drug_n	162-186	false
1,3-difluoro-2-propanol	drug_n	107-129	1,3-difluoro-2-propanol	drug_n	257-279	false
(-)-erythro-fluorocitrate	drug_n	162-186	1,3-difluoro-2-propanol	drug_n	257-279	false

DDI-MedLine.d125.s7	However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo.
4-methylpyrazole	drug	27-42	1,3-difluoroacetone	drug_n	96-114	false
4-methylpyrazole	drug	27-42	(-)-erythro-fluorocitrate	drug_n	174-198	false
1,3-difluoroacetone	drug_n	96-114	(-)-erythro-fluorocitrate	drug_n	174-198	false

DDI-MedLine.d125.s8	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
4-methylpyrazole	drug	62-77	1,3-difluoro-2-propanol	drug_n	108-130	true
4-methylpyrazole	drug	62-77	1,3-difluoro-2-propanol	drug_n	224-246	false
4-methylpyrazole	drug	62-77	1,3-difluoroacetone	drug_n	251-269	false
1,3-difluoro-2-propanol	drug_n	108-130	1,3-difluoro-2-propanol	drug_n	224-246	false
1,3-difluoro-2-propanol	drug_n	108-130	1,3-difluoroacetone	drug_n	251-269	false
1,3-difluoro-2-propanol	drug_n	224-246	1,3-difluoroacetone	drug_n	251-269	false

DDI-MedLine.d129.s0	Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
Green tea polyphenols	drug	0-20	enhancers	drug	32-40	false

DDI-MedLine.d129.s3	n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid.
n-dodecyl gallate	drug	0-16	tannic acid	drug	128-138	false

DDI-MedLine.d86.s0	Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
diltiazem	drug	57-65	sirolimus	drug	71-79	true

DDI-MedLine.d86.s1	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.
sirolimus	drug	60-68	macrolide immunosuppressant	group	73-99	false
sirolimus	drug	60-68	calcium channel blocker	group	132-154	false
sirolimus	drug	60-68	diltiazem	drug	156-164	false
macrolide immunosuppressant	group	73-99	calcium channel blocker	group	132-154	false
macrolide immunosuppressant	group	73-99	diltiazem	drug	156-164	false
calcium channel blocker	group	132-154	diltiazem	drug	156-164	false

DDI-MedLine.d86.s2	Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists.
immunosuppressive drugs	group	82-104	calcium antagonists	group	154-172	false

DDI-MedLine.d86.s3	METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together.
sirolimus	drug	176-184	diltiazem	drug	216-224	false

DDI-MedLine.d86.s5	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
sirolimus	drug	66-74	diltiazem	drug	253-261	true
sirolimus	drug	66-74	sirolimus	drug	323-331	false
diltiazem	drug	253-261	sirolimus	drug	323-331	false

DDI-MedLine.d86.s6	Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
sirolimus	drug	54-62	sirolimus	drug	111-119	false
sirolimus	drug	54-62	diltiazem	drug	136-144	false
sirolimus	drug	111-119	diltiazem	drug	136-144	true

DDI-MedLine.d86.s7	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	drug	87-95	desacetyldiltiazem	drug_n	98-115	false
diltiazem	drug	87-95	desmethyldiltiazem	drug_n	122-139	false
diltiazem	drug	87-95	sirolimus	drug	182-190	false
diltiazem	drug	87-95	diltiazem	drug	231-239	false
desacetyldiltiazem	drug_n	98-115	desmethyldiltiazem	drug_n	122-139	false
desacetyldiltiazem	drug_n	98-115	sirolimus	drug	182-190	false
desacetyldiltiazem	drug_n	98-115	diltiazem	drug	231-239	false
desmethyldiltiazem	drug_n	122-139	sirolimus	drug	182-190	false
desmethyldiltiazem	drug_n	122-139	diltiazem	drug	231-239	false
sirolimus	drug	182-190	diltiazem	drug	231-239	false

DDI-MedLine.d86.s8	CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
diltiazem	drug	25-33	sirolimus	drug	68-76	true
diltiazem	drug	25-33	sirolimus	drug	145-153	false
sirolimus	drug	68-76	sirolimus	drug	145-153	false

DDI-MedLine.d86.s9	Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
sirolimus	drug	72-80	diltiazem	drug	82-90	true
sirolimus	drug	72-80	sirolimus	drug	117-125	false
diltiazem	drug	82-90	sirolimus	drug	117-125	false

DDI-MedLine.d99.s0	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Fluvoxamine	drug	0-10	tolbutamide	drug	63-73	true

DDI-MedLine.d99.s1	OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
fluvoxamine	drug	64-74	tolbutamide	drug	80-90	false
fluvoxamine	drug	64-74	fluvoxamine	drug	108-118	false
tolbutamide	drug	80-90	fluvoxamine	drug	108-118	false

DDI-MedLine.d99.s8	Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.
tolbutamide	drug	24-34	tolbutamide	drug	64-74	false
tolbutamide	drug	24-34	4-hydroxytolbutamide	drug_n	101-120	false
tolbutamide	drug	24-34	carboxytolbutamide	drug_n	126-143	false
tolbutamide	drug	64-74	4-hydroxytolbutamide	drug_n	101-120	false
tolbutamide	drug	64-74	carboxytolbutamide	drug_n	126-143	false
4-hydroxytolbutamide	drug_n	101-120	carboxytolbutamide	drug_n	126-143	false

DDI-MedLine.d99.s9	RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
fluvoxamine	drug	31-41	tolbutamide	drug	131-141	true

DDI-MedLine.d99.s11	The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).
4-hydroxytolbutamide	drug_n	26-45	carboxytolbutamide	drug_n	51-68	false
4-hydroxytolbutamide	drug_n	26-45	tolbutamide	drug	179-189	false
4-hydroxytolbutamide	drug_n	26-45	tolbutamide	drug	265-275	false
carboxytolbutamide	drug_n	51-68	tolbutamide	drug	179-189	false
carboxytolbutamide	drug_n	51-68	tolbutamide	drug	265-275	false
tolbutamide	drug	179-189	tolbutamide	drug	265-275	false

DDI-MedLine.d140.s0	Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
everolimus	drug	27-36	cyclosporine	drug	182-193	false

DDI-MedLine.d140.s1	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
everolimus	drug	82-91	cyclosporine	drug	97-108	false
everolimus	drug	82-91	ciclosporin	drug	116-126	false
cyclosporine	drug	97-108	ciclosporin	drug	116-126	false

DDI-MedLine.d140.s2	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone.
everolimus	drug	127-136	cyclosporine	drug	197-208	false
everolimus	drug	127-136	prednisone	drug	214-223	false
cyclosporine	drug	197-208	prednisone	drug	214-223	false

DDI-MedLine.d140.s3	Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.
everolimus	drug	43-52	cyclosporine	drug	58-69	false

DDI-MedLine.d140.s6	Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA.
cyclosporine	drug	25-36	everolimus	drug	89-98	false

DDI-MedLine.d140.s13	Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively).
Cyclosporine	drug	0-11	everolimus	drug	152-161	false

DDI-MedLine.d140.s15	For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.
everolimus	drug	22-31	cyclosporine	drug	77-88	false

DDI-MedLine.d87.s0	ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
ADL 8-2698	drug	0-9	morphine	drug	114-121	true

DDI-MedLine.d87.s1	ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
ADL-8-2698	drug	0-9	peripherally restricted opioid antagonist	group	22-62	false
ADL-8-2698	drug	0-9	opioid	group	93-98	true
peripherally restricted opioid antagonist	group	22-62	opioid	group	93-98	false

DDI-MedLine.d87.s2	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study.
morphine	drug	157-164	ADL 8-2698	drug	195-204	false
morphine	drug	157-164	morphine	drug	229-236	false
ADL 8-2698	drug	195-204	morphine	drug	229-236	false

DDI-MedLine.d87.s4	Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
Morphine	drug	0-7	ADL 8-2698	drug	106-115	true

DDI-MedLine.d87.s5	Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo.
ADL 8-2698	drug	89-98	morphine	drug	134-141	false

DDI-MedLine.d87.s7	Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002).
Morphine	drug	0-7	ADL 8-2698	drug	61-70	false

DDI-MedLine.d87.s8	We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
ADL 8-2698	drug	17-26	morphine	drug	37-44	true

DDI-MedLine.d25.s0	Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
simvastatin	drug	55-65	clarithromycin	drug	71-84	true

DDI-MedLine.d25.s1	OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin.
clarithromycin	drug	80-93	simvastatin	drug	99-109	false

DDI-MedLine.d25.s9	DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
Clarithromycin	drug	12-25	simvastatin	drug	93-103	true

DDI-MedLine.d25.s10	The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
macrolide antibiotics	group	34-54	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	group	66-128	true

DDI-MedLine.d25.s12	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
Macrolide antibiotics	group	13-33	HMG-CoA reductase inhibitors	group	61-88	false
Macrolide antibiotics	group	13-33	atorvastatin	drug	128-139	true
Macrolide antibiotics	group	13-33	cerivastatin	drug	142-153	true
Macrolide antibiotics	group	13-33	lovastatin	drug	156-165	true
Macrolide antibiotics	group	13-33	simvastatin	drug	168-178	true
HMG-CoA reductase inhibitors	group	61-88	atorvastatin	drug	128-139	false
HMG-CoA reductase inhibitors	group	61-88	cerivastatin	drug	142-153	false
HMG-CoA reductase inhibitors	group	61-88	lovastatin	drug	156-165	false
HMG-CoA reductase inhibitors	group	61-88	simvastatin	drug	168-178	false
atorvastatin	drug	128-139	cerivastatin	drug	142-153	false
atorvastatin	drug	128-139	lovastatin	drug	156-165	false
atorvastatin	drug	128-139	simvastatin	drug	168-178	false
cerivastatin	drug	142-153	lovastatin	drug	156-165	false
cerivastatin	drug	142-153	simvastatin	drug	168-178	false
lovastatin	drug	156-165	simvastatin	drug	168-178	false

DDI-MedLine.d0.s0	The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
phenytoin	drug	27-35	quetiapine	drug	92-101	false

DDI-MedLine.d0.s1	Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Quetiapine fumarate	drug	0-18	Seroquel	brand	22-29	false
Quetiapine fumarate	drug	0-18	atypical antipsychotic	group	55-76	false
Seroquel	brand	22-29	atypical antipsychotic	group	55-76	false

DDI-MedLine.d0.s4	This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
phenytoin	drug	71-79	quetiapine	drug	134-143	true

DDI-MedLine.d111.s2	Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	0-12	lidocaine	drug	15-23	false
Acetaminophen	drug	0-12	phenobarbital	drug	26-38	false
Acetaminophen	drug	0-12	quinidine	drug	41-49	false
Acetaminophen	drug	0-12	theophylline	drug	52-63	false
Acetaminophen	drug	0-12	valproic acid	drug	70-82	false
lidocaine	drug	15-23	phenobarbital	drug	26-38	false
lidocaine	drug	15-23	quinidine	drug	41-49	false
lidocaine	drug	15-23	theophylline	drug	52-63	false
lidocaine	drug	15-23	valproic acid	drug	70-82	false
phenobarbital	drug	26-38	quinidine	drug	41-49	false
phenobarbital	drug	26-38	theophylline	drug	52-63	false
phenobarbital	drug	26-38	valproic acid	drug	70-82	false
quinidine	drug	41-49	theophylline	drug	52-63	false
quinidine	drug	41-49	valproic acid	drug	70-82	false
theophylline	drug	52-63	valproic acid	drug	70-82	false

DDI-MedLine.d111.s4	The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital.
acetaminophen	drug	70-82	phenobarbital	drug	84-96	false

DDI-MedLine.d111.s5	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
acetaminophen	drug	0-12	theophylline	drug	14-25	false
acetaminophen	drug	0-12	lidocaine	drug	28-36	false
acetaminophen	drug	0-12	quinidine	drug	38-46	false
acetaminophen	drug	0-12	phenobarbital	drug	49-61	false
acetaminophen	drug	0-12	acetaminophen	drug	63-75	false
acetaminophen	drug	0-12	phenobarbital	drug	78-90	false
acetaminophen	drug	0-12	valproic acid	drug	92-104	false
acetaminophen	drug	0-12	quinidine	drug	107-115	false
acetaminophen	drug	0-12	lidocaine	drug	117-125	false
acetaminophen	drug	0-12	theophylline	drug	128-139	false
acetaminophen	drug	0-12	acetaminophen	drug	141-153	false
acetaminophen	drug	0-12	valproic acid	drug	160-172	false
acetaminophen	drug	0-12	phenobarbital	drug	174-186	false
theophylline	drug	14-25	lidocaine	drug	28-36	false
theophylline	drug	14-25	quinidine	drug	38-46	false
theophylline	drug	14-25	phenobarbital	drug	49-61	false
theophylline	drug	14-25	acetaminophen	drug	63-75	false
theophylline	drug	14-25	phenobarbital	drug	78-90	false
theophylline	drug	14-25	valproic acid	drug	92-104	false
theophylline	drug	14-25	quinidine	drug	107-115	false
theophylline	drug	14-25	lidocaine	drug	117-125	false
theophylline	drug	14-25	theophylline	drug	128-139	false
theophylline	drug	14-25	acetaminophen	drug	141-153	false
theophylline	drug	14-25	valproic acid	drug	160-172	false
theophylline	drug	14-25	phenobarbital	drug	174-186	false
lidocaine	drug	28-36	quinidine	drug	38-46	false
lidocaine	drug	28-36	phenobarbital	drug	49-61	false
lidocaine	drug	28-36	acetaminophen	drug	63-75	false
lidocaine	drug	28-36	phenobarbital	drug	78-90	false
lidocaine	drug	28-36	valproic acid	drug	92-104	false
lidocaine	drug	28-36	quinidine	drug	107-115	false
lidocaine	drug	28-36	lidocaine	drug	117-125	false
lidocaine	drug	28-36	theophylline	drug	128-139	false
lidocaine	drug	28-36	acetaminophen	drug	141-153	false
lidocaine	drug	28-36	valproic acid	drug	160-172	false
lidocaine	drug	28-36	phenobarbital	drug	174-186	false
quinidine	drug	38-46	phenobarbital	drug	49-61	false
quinidine	drug	38-46	acetaminophen	drug	63-75	false
quinidine	drug	38-46	phenobarbital	drug	78-90	false
quinidine	drug	38-46	valproic acid	drug	92-104	false
quinidine	drug	38-46	quinidine	drug	107-115	false
quinidine	drug	38-46	lidocaine	drug	117-125	false
quinidine	drug	38-46	theophylline	drug	128-139	false
quinidine	drug	38-46	acetaminophen	drug	141-153	false
quinidine	drug	38-46	valproic acid	drug	160-172	false
quinidine	drug	38-46	phenobarbital	drug	174-186	false
phenobarbital	drug	49-61	acetaminophen	drug	63-75	false
phenobarbital	drug	49-61	phenobarbital	drug	78-90	false
phenobarbital	drug	49-61	valproic acid	drug	92-104	false
phenobarbital	drug	49-61	quinidine	drug	107-115	false
phenobarbital	drug	49-61	lidocaine	drug	117-125	false
phenobarbital	drug	49-61	theophylline	drug	128-139	false
phenobarbital	drug	49-61	acetaminophen	drug	141-153	false
phenobarbital	drug	49-61	valproic acid	drug	160-172	false
phenobarbital	drug	49-61	phenobarbital	drug	174-186	false
acetaminophen	drug	63-75	phenobarbital	drug	78-90	false
acetaminophen	drug	63-75	valproic acid	drug	92-104	false
acetaminophen	drug	63-75	quinidine	drug	107-115	false
acetaminophen	drug	63-75	lidocaine	drug	117-125	false
acetaminophen	drug	63-75	theophylline	drug	128-139	false
acetaminophen	drug	63-75	acetaminophen	drug	141-153	false
acetaminophen	drug	63-75	valproic acid	drug	160-172	false
acetaminophen	drug	63-75	phenobarbital	drug	174-186	false
phenobarbital	drug	78-90	valproic acid	drug	92-104	false
phenobarbital	drug	78-90	quinidine	drug	107-115	false
phenobarbital	drug	78-90	lidocaine	drug	117-125	false
phenobarbital	drug	78-90	theophylline	drug	128-139	false
phenobarbital	drug	78-90	acetaminophen	drug	141-153	false
phenobarbital	drug	78-90	valproic acid	drug	160-172	false
phenobarbital	drug	78-90	phenobarbital	drug	174-186	false
valproic acid	drug	92-104	quinidine	drug	107-115	false
valproic acid	drug	92-104	lidocaine	drug	117-125	false
valproic acid	drug	92-104	theophylline	drug	128-139	false
valproic acid	drug	92-104	acetaminophen	drug	141-153	false
valproic acid	drug	92-104	valproic acid	drug	160-172	false
valproic acid	drug	92-104	phenobarbital	drug	174-186	false
quinidine	drug	107-115	lidocaine	drug	117-125	false
quinidine	drug	107-115	theophylline	drug	128-139	false
quinidine	drug	107-115	acetaminophen	drug	141-153	false
quinidine	drug	107-115	valproic acid	drug	160-172	false
quinidine	drug	107-115	phenobarbital	drug	174-186	false
lidocaine	drug	117-125	theophylline	drug	128-139	false
lidocaine	drug	117-125	acetaminophen	drug	141-153	false
lidocaine	drug	117-125	valproic acid	drug	160-172	false
lidocaine	drug	117-125	phenobarbital	drug	174-186	false
theophylline	drug	128-139	acetaminophen	drug	141-153	false
theophylline	drug	128-139	valproic acid	drug	160-172	false
theophylline	drug	128-139	phenobarbital	drug	174-186	false
acetaminophen	drug	141-153	valproic acid	drug	160-172	false
acetaminophen	drug	141-153	phenobarbital	drug	174-186	false
valproic acid	drug	160-172	phenobarbital	drug	174-186	false

DDI-MedLine.d111.s7	Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.
phenobarbital	drug	24-36	quinidine	drug	39-47	false
phenobarbital	drug	24-36	theophylline	drug	54-65	false
phenobarbital	drug	24-36	ethanol	drug	127-133	false
quinidine	drug	39-47	theophylline	drug	54-65	false
quinidine	drug	39-47	ethanol	drug	127-133	false
theophylline	drug	54-65	ethanol	drug	127-133	false

DDI-MedLine.d111.s9	Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
Acetaminophen	drug	0-12	theophylline	drug	40-51	true

DDI-MedLine.d111.s10	Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
Theophylline	drug	0-11	acetaminophen	drug	38-50	true

DDI-MedLine.d111.s12	Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
Valproic acid	drug	0-12	phenobarbital	drug	36-48	true

DDI-MedLine.d111.s14	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	15-27	theophylline	drug	34-45	true
acetaminophen	drug	15-27	phenobarbital	drug	48-60	false
acetaminophen	drug	15-27	acetaminophen	drug	67-79	false
acetaminophen	drug	15-27	valproic acid	drug	86-98	false
acetaminophen	drug	15-27	phenobarbital	drug	105-117	false
theophylline	drug	34-45	phenobarbital	drug	48-60	false
theophylline	drug	34-45	acetaminophen	drug	67-79	false
theophylline	drug	34-45	valproic acid	drug	86-98	false
theophylline	drug	34-45	phenobarbital	drug	105-117	false
phenobarbital	drug	48-60	acetaminophen	drug	67-79	true
phenobarbital	drug	48-60	valproic acid	drug	86-98	false
phenobarbital	drug	48-60	phenobarbital	drug	105-117	false
acetaminophen	drug	67-79	valproic acid	drug	86-98	false
acetaminophen	drug	67-79	phenobarbital	drug	105-117	false
valproic acid	drug	86-98	phenobarbital	drug	105-117	true

DDI-MedLine.d60.s2	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
phenytoin	drug	27-35	fluvoxamine	drug	93-103	false
phenytoin	drug	27-35	phenytoin	drug	154-162	false
phenytoin	drug	27-35	drugs	drug	174-178	false
fluvoxamine	drug	93-103	phenytoin	drug	154-162	false
fluvoxamine	drug	93-103	drugs	drug	174-178	false
phenytoin	drug	154-162	drugs	drug	174-178	false

DDI-MedLine.d60.s3	During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed.
phenytoin	drug	7-15	phenytoin	drug	77-85	false

DDI-MedLine.d60.s4	The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1).
CYP2C9	drug	17-22	CYP2C9	drug	127-132	false

DDI-MedLine.d60.s5	The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
CYP2C9	drug	54-59	fluvoxamine	drug	73-83	false

DDI-MedLine.d123.s2	Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.
galangin	drug	35-42	vancomycin	drug	73-82	false

DDI-MedLine.d137.s0	Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
Glucose	drug	0-6	insulin	drug	12-18	false

DDI-MedLine.d137.s1	AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.
insulin	drug	40-46	glucose	drug	52-58	false

DDI-MedLine.d137.s9	Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
glucose	drug	24-30	insulin	drug	36-42	false
glucose	drug	24-30	somatostatin	drug	63-74	false
insulin	drug	36-42	somatostatin	drug	63-74	false

DDI-MedLine.d137.s10	CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation.
Glucose	drug	28-34	insulin	drug	40-46	false

DDI-MedLine.d124.s0	Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
levofloxacin	drug	28-39	oxycodone	drug	45-53	false

DDI-MedLine.d124.s1	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
trovafloxacin	drug	90-102	ciprofloxacin	drug	108-120	false
trovafloxacin	drug	90-102	opiate	group	174-179	true
trovafloxacin	drug	90-102	morphine	drug	189-196	true
ciprofloxacin	drug	108-120	opiate	group	174-179	true
ciprofloxacin	drug	108-120	morphine	drug	189-196	true
opiate	group	174-179	morphine	drug	189-196	false

DDI-MedLine.d124.s2	This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures.
trovafloxacin	drug	67-79	ciprofloxacin	drug	85-97	false

DDI-MedLine.d124.s3	The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin.
oxycodone	drug	74-82	levofloxacin	drug	88-99	false

DDI-MedLine.d124.s6	1 hour after starting the oxycodone or levofloxacin 500 mg p.o.
oxycodone	drug	26-34	levofloxacin	drug	39-50	false

DDI-MedLine.d124.s9	There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.
levofloxacin	drug	173-184	levofloxacin	drug	193-204	false
levofloxacin	drug	173-184	oxycodone	drug	206-214	false
levofloxacin	drug	193-204	oxycodone	drug	206-214	false

DDI-MedLine.d124.s10	It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
oxycodone	drug	27-35	levofloxacin	drug	41-52	false

DDI-MedLine.d105.s0	Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
azithromycin	drug	21-32	zidovudine	drug	56-65	false
azithromycin	drug	21-32	dideoxyinosine	drug	71-84	false
zidovudine	drug	56-65	dideoxyinosine	drug	71-84	false

DDI-MedLine.d105.s1	Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine.
azithromycin	drug	80-91	zidovudine	drug	110-119	false
azithromycin	drug	80-91	dideoxyinosine	drug	125-138	false
zidovudine	drug	110-119	dideoxyinosine	drug	125-138	false

DDI-MedLine.d105.s3	The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.
zidovudine	drug	4-13	azithromycin	drug	56-67	false
zidovudine	drug	4-13	zidovudine	drug	180-189	false
azithromycin	drug	56-67	zidovudine	drug	180-189	false

DDI-MedLine.d105.s4	Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21.
dideoxyinosine	drug	32-45	azithromycin	drug	91-102	false

DDI-MedLine.d105.s7	Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
Azithromycin	drug	0-11	zidovudine	drug	62-71	false
Azithromycin	drug	0-11	zidovudine	drug	114-123	true
Azithromycin	drug	0-11	zidovudine	drug	196-205	true
zidovudine	drug	62-71	zidovudine	drug	114-123	false
zidovudine	drug	62-71	zidovudine	drug	196-205	false
zidovudine	drug	114-123	zidovudine	drug	196-205	false

DDI-MedLine.d105.s8	Azithromycin had no significant effect on dideoxyinosine pharmacokinetics.
Azithromycin	drug	0-11	dideoxyinosine	drug	42-55	false

DDI-MedLine.d105.s9	Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.
azithromycin	drug	60-71	zidovudine	drug	112-121	false
azithromycin	drug	60-71	dideoxyinosine	drug	127-140	false
zidovudine	drug	112-121	dideoxyinosine	drug	127-140	false

DDI-MedLine.d67.s0	Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
diazepam	drug	10-17	midazolam	drug	23-31	false
diazepam	drug	10-17	morphine	drug	66-73	false
diazepam	drug	10-17	metamizol	drug	76-84	false
diazepam	drug	10-17	indomethacin	drug	90-101	false
midazolam	drug	23-31	morphine	drug	66-73	false
midazolam	drug	23-31	metamizol	drug	76-84	false
midazolam	drug	23-31	indomethacin	drug	90-101	false
morphine	drug	66-73	metamizol	drug	76-84	false
morphine	drug	66-73	indomethacin	drug	90-101	false
metamizol	drug	76-84	indomethacin	drug	90-101	false

DDI-MedLine.d67.s1	The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	17-25	diazepam	drug	31-38	false
midazolam	drug	17-25	morphine	drug	69-76	false
midazolam	drug	17-25	metamizol	drug	90-98	false
midazolam	drug	17-25	indomethacin	drug	116-127	false
diazepam	drug	31-38	morphine	drug	69-76	false
diazepam	drug	31-38	metamizol	drug	90-98	false
diazepam	drug	31-38	indomethacin	drug	116-127	false
morphine	drug	69-76	metamizol	drug	90-98	false
morphine	drug	69-76	indomethacin	drug	116-127	false
metamizol	drug	90-98	indomethacin	drug	116-127	false

DDI-MedLine.d67.s3	Benzodiazepines were administered to mice 30 min before applying the analgesic drugs.
Benzodiazepines	group	0-14	analgesic drugs	group	69-83	false

DDI-MedLine.d67.s5	Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
Diazepam	drug	0-7	morphine	drug	60-67	true
Diazepam	drug	0-7	morphine	drug	121-128	false
morphine	drug	60-67	morphine	drug	121-128	false

DDI-MedLine.d67.s6	Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
diazepam	drug	11-18	metamizol	drug	60-68	true
diazepam	drug	11-18	indomethacin	drug	104-115	true
metamizol	drug	60-68	indomethacin	drug	104-115	false

DDI-MedLine.d67.s7	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
Midazolam	drug	0-8	morphine	drug	92-99	true
Midazolam	drug	0-8	metamizol	drug	102-110	true
Midazolam	drug	0-8	indomethacin	drug	146-157	true
morphine	drug	92-99	metamizol	drug	102-110	false
morphine	drug	92-99	indomethacin	drug	146-157	false
metamizol	drug	102-110	indomethacin	drug	146-157	false

DDI-MedLine.d102.s0	Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
estradiol	drug	13-21	progesterone	drug	27-38	false
estradiol	drug	13-21	noradrenaline	drug	84-96	false
progesterone	drug	27-38	noradrenaline	drug	84-96	false

DDI-MedLine.d102.s1	The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta.
estradiol	drug	78-86	progesterone	drug	96-107	false
estradiol	drug	78-86	noradrenaline	drug	128-140	false
progesterone	drug	96-107	noradrenaline	drug	128-140	false

DDI-MedLine.d102.s3	injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days.
estradiol	drug	45-53	progesterone	drug	96-107	false

DDI-MedLine.d102.s5	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
estradiol	drug	70-78	noradrenaline	drug	109-121	true

DDI-MedLine.d102.s6	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
estradiol	drug	42-50	noradrenaline	drug	80-92	true
estradiol	drug	42-50	progesterone	drug	121-132	false
estradiol	drug	42-50	progesterone	drug	139-150	false
estradiol	drug	42-50	estradiol	drug	159-167	false
noradrenaline	drug	80-92	progesterone	drug	121-132	false
noradrenaline	drug	80-92	progesterone	drug	139-150	false
noradrenaline	drug	80-92	estradiol	drug	159-167	false
progesterone	drug	121-132	progesterone	drug	139-150	false
progesterone	drug	121-132	estradiol	drug	159-167	false
progesterone	drug	139-150	estradiol	drug	159-167	false

DDI-MedLine.d1.s1	Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular.
erection-supporting medication	group	26-55	erection-supporting medication	group	163-192	false

DDI-MedLine.d1.s5	Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
Sildenafil	drug	0-9	long-acting nitrates	group	48-67	true
Sildenafil	drug	0-9	short-acting nitrates	group	92-112	true
long-acting nitrates	group	48-67	short-acting nitrates	group	92-112	false

DDI-MedLine.d1.s6	No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors.
beta-receptor blockers	group	40-61	calcium antagonists	group	64-82	false
beta-receptor blockers	group	40-61	thiazide diuretics	group	85-92;103-111	false
beta-receptor blockers	group	40-61	loop diuretics	group	98-111	false
beta-receptor blockers	group	40-61	ACE inhibitors	group	117-130	false
calcium antagonists	group	64-82	thiazide diuretics	group	85-92;103-111	false
calcium antagonists	group	64-82	loop diuretics	group	98-111	false
calcium antagonists	group	64-82	ACE inhibitors	group	117-130	false
thiazide diuretics	group	85-92;103-111	loop diuretics	group	98-111	false
thiazide diuretics	group	85-92;103-111	ACE inhibitors	group	117-130	false
loop diuretics	group	98-111	ACE inhibitors	group	117-130	false

DDI-MedLine.d46.s0	Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
fluoxetine	drug	33-42	cisapride	drug	47-55	false

DDI-MedLine.d46.s1	STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men.
fluoxetine	drug	43-52	cisapride	drug	107-115	false

DDI-MedLine.d46.s9	and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
cisapride	drug	26-34	fluoxetine	drug	72-81	false

DDI-MedLine.d46.s13	Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
fluoxetine	drug	20-29	cisapride	drug	55-63	true

DDI-MedLine.d46.s14	There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine.
cisapride	drug	96-104	fluoxetine	drug	120-129	false

DDI-MedLine.d46.s15	Cisapride was well tolerated when administered alone or with fluoxetine.
Cisapride	drug	0-8	fluoxetine	drug	61-70	false

DDI-MedLine.d46.s16	CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.
Cisapride	drug	12-20	fluoxetine	drug	98-107	false

DDI-MedLine.d83.s1	Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia.
Olanzapine	drug	0-9	thienobenzodiazepine derivative	group	14-44	false
Olanzapine	drug	0-9	second generation (atypical) antipsychotic agent	group	52-99	false
thienobenzodiazepine derivative	group	14-44	second generation (atypical) antipsychotic agent	group	52-99	false

DDI-MedLine.d83.s3	In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms.
olanzapine	drug	86-95	haloperidol	drug	142-152	false

DDI-MedLine.d83.s4	The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
olanzapine	drug	76-85	haloperidol	drug	97-107	false

DDI-MedLine.d83.s5	In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	drug	57-66	risperidone	drug	72-82	false
olanzapine	drug	57-66	olanzapine	drug	85-94	false
olanzapine	drug	57-66	risperidone	drug	159-169	false
risperidone	drug	72-82	olanzapine	drug	85-94	false
risperidone	drug	72-82	risperidone	drug	159-169	false
olanzapine	drug	85-94	risperidone	drug	159-169	false

DDI-MedLine.d83.s6	In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
risperidone	drug	75-85	olanzapine	drug	117-126	false

DDI-MedLine.d83.s7	Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol.
olanzapine	drug	53-62	risperidone	drug	204-214	false
olanzapine	drug	53-62	haloperidol	drug	219-229	false
risperidone	drug	204-214	haloperidol	drug	219-229	false

DDI-MedLine.d83.s8	However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder.
olanzapine	drug	99-108	risperidone	drug	114-124	false

DDI-MedLine.d83.s9	Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology.
olanzapine	drug	30-39	olanzapine	drug	158-167	false

DDI-MedLine.d83.s10	Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone.
Olanzapine	drug	0-9	haloperidol	drug	79-89	false
Olanzapine	drug	0-9	risperidone	drug	95-105	false
haloperidol	drug	79-89	risperidone	drug	95-105	false

DDI-MedLine.d83.s11	In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval.
olanzapine	drug	13-22	clozapine	drug	86-94	false
olanzapine	drug	13-22	risperidone	drug	155-165	false
clozapine	drug	86-94	risperidone	drug	155-165	false

DDI-MedLine.d83.s13	In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine.
haloperidol	drug	19-29	olanzapine	drug	95-104	false
haloperidol	drug	19-29	risperidone	drug	206-216	false
haloperidol	drug	19-29	olanzapine	drug	284-293	false
olanzapine	drug	95-104	risperidone	drug	206-216	false
olanzapine	drug	95-104	olanzapine	drug	284-293	false
risperidone	drug	206-216	olanzapine	drug	284-293	false

DDI-MedLine.d83.s15	Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol.
olanzapine	drug	40-49	haloperidol	drug	174-184	false

DDI-MedLine.d83.s16	Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug.
risperidone	drug	14-24	olanzapine	drug	27-36	false

DDI-MedLine.d83.s17	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone.
Olanzapine	drug	0-9	haloperidol	drug	124-134	false
Olanzapine	drug	0-9	risperidone	drug	171-181	false
haloperidol	drug	124-134	risperidone	drug	171-181	false

DDI-MedLine.d83.s18	CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia.
Olanzapine	drug	13-22	haloperidol	drug	83-93	false

DDI-MedLine.d83.s19	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
haloperidol	drug	77-87	risperidone	drug	93-103	false
haloperidol	drug	77-87	olanzapine	drug	180-189	false
risperidone	drug	93-103	olanzapine	drug	180-189	false

DDI-MedLine.d132.s0	The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
non-nucleoside reverse transcriptase inhibitors	group	22-68	antiretroviral	group	73-86	false

DDI-MedLine.d132.s1	The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	27-72	NNRTI	group	75-79	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	antiretroviral	group	101-114	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	protease inhibitor	group	147-164	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	PI	group	167-168	false
NNRTI	group	75-79	antiretroviral	group	101-114	false
NNRTI	group	75-79	protease inhibitor	group	147-164	false
NNRTI	group	75-79	PI	group	167-168	false
antiretroviral	group	101-114	protease inhibitor	group	147-164	false
antiretroviral	group	101-114	PI	group	167-168	false
protease inhibitor	group	147-164	PI	group	167-168	false

DDI-MedLine.d132.s2	NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.
NNRTI	group	0-4	PI	group	54-55	false

DDI-MedLine.d132.s3	No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine).
efavirenz	drug	90-98	nevirapine	drug	101-110	false
efavirenz	drug	90-98	delavirdine	drug	115-125	false
nevirapine	drug	101-110	delavirdine	drug	115-125	false

DDI-MedLine.d132.s4	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.
efavirenz	drug	5-13	nevirapine	drug	19-28	false
efavirenz	drug	5-13	PI	group	76-77	false
efavirenz	drug	5-13	indinavir	drug	79-87	false
efavirenz	drug	5-13	nevirapine	drug	166-175	false
efavirenz	drug	5-13	efavirenz	drug	216-224	false
nevirapine	drug	19-28	PI	group	76-77	false
nevirapine	drug	19-28	indinavir	drug	79-87	false
nevirapine	drug	19-28	nevirapine	drug	166-175	false
nevirapine	drug	19-28	efavirenz	drug	216-224	false
PI	group	76-77	indinavir	drug	79-87	false
PI	group	76-77	nevirapine	drug	166-175	false
PI	group	76-77	efavirenz	drug	216-224	false
indinavir	drug	79-87	nevirapine	drug	166-175	false
indinavir	drug	79-87	efavirenz	drug	216-224	false
nevirapine	drug	166-175	efavirenz	drug	216-224	false

DDI-MedLine.d132.s5	A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir.
nevirapine	drug	38-47	PI	group	72-73	false
nevirapine	drug	38-47	nelfinavir	drug	75-84	false
PI	group	72-73	nelfinavir	drug	75-84	false

DDI-MedLine.d132.s6	Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist.
nevirapine	drug	72-81	delavirdine	drug	87-97	false

DDI-MedLine.d132.s8	The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads.
efavirenz	drug	19-27	indinavir	drug	34-42	false

DDI-MedLine.d132.s10	Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.
Efavirenz	drug	0-8	nelfinavir	drug	44-53	false

DDI-MedLine.d42.s4	METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction.
sildenafil	drug	84-93	sildenafil	drug	291-300	false
sildenafil	drug	84-93	Viagra	brand	303-308	false
sildenafil	drug	291-300	Viagra	brand	303-308	false

DDI-MedLine.d42.s5	RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]).
Sildenafil	drug	9-18	selective serotonin reuptake inhibitors	group	205-243	false
Sildenafil	drug	9-18	SSRIs	group	246-250	false
selective serotonin reuptake inhibitors	group	205-243	SSRIs	group	246-250	false

DDI-MedLine.d42.s9	however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
nitrate	group	81-87	sildenafil	drug	179-188	true

DDI-MedLine.d42.s10	In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil.
sildenafil	drug	99-108	sildenafil	drug	199-208	false

DDI-MedLine.d38.s0	Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
hydrocortisone	drug	6-19	d-amphetamine	drug	76-88	false

DDI-MedLine.d38.s2	However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans.
glucocorticoids	group	35-49	psychostimulants	group	95-110	false

DDI-MedLine.d38.s3	OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine.
hydrocortisone	drug	44-57	d-amphetamine	drug	116-128	false

DDI-MedLine.d38.s4	METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design.
Hydrocortisone	drug	9-22	d-amphetamine	drug	37-49	false

DDI-MedLine.d38.s8	However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine.
hydrocortisone	drug	9-22	d-amphetamine	drug	115-127	false

DDI-MedLine.d38.s9	CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.
glucocorticoids	group	43-57	d-amphetamine	drug	184-196	false

DDI-MedLine.d23.s0	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
ketamine	drug	15-22	Innovar	brand	31-37	false
ketamine	drug	15-22	digitalis	group	53-61	false
Innovar	brand	31-37	digitalis	group	53-61	false

DDI-MedLine.d23.s1	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
digitalis	group	19-27	ketamine	drug	65-72	false
digitalis	group	19-27	Innovar Vet	brand	75-85	false
digitalis	group	19-27	pentobarbital	drug	91-103	false
digitalis	group	19-27	ouabain	drug	120-126	false
digitalis	group	19-27	ouabain	drug	213-219	false
digitalis	group	19-27	ketamine	drug	227-234	false
digitalis	group	19-27	Innovar	brand	239-245	false
digitalis	group	19-27	pentobarbital	drug	257-269	false
ketamine	drug	65-72	Innovar Vet	brand	75-85	false
ketamine	drug	65-72	pentobarbital	drug	91-103	false
ketamine	drug	65-72	ouabain	drug	120-126	true
ketamine	drug	65-72	ouabain	drug	213-219	false
ketamine	drug	65-72	ketamine	drug	227-234	false
ketamine	drug	65-72	Innovar	brand	239-245	false
ketamine	drug	65-72	pentobarbital	drug	257-269	false
Innovar Vet	brand	75-85	pentobarbital	drug	91-103	false
Innovar Vet	brand	75-85	ouabain	drug	120-126	true
Innovar Vet	brand	75-85	ouabain	drug	213-219	false
Innovar Vet	brand	75-85	ketamine	drug	227-234	false
Innovar Vet	brand	75-85	Innovar	brand	239-245	false
Innovar Vet	brand	75-85	pentobarbital	drug	257-269	false
pentobarbital	drug	91-103	ouabain	drug	120-126	true
pentobarbital	drug	91-103	ouabain	drug	213-219	false
pentobarbital	drug	91-103	ketamine	drug	227-234	false
pentobarbital	drug	91-103	Innovar	brand	239-245	false
pentobarbital	drug	91-103	pentobarbital	drug	257-269	false
ouabain	drug	120-126	ouabain	drug	213-219	false
ouabain	drug	120-126	ketamine	drug	227-234	false
ouabain	drug	120-126	Innovar	brand	239-245	false
ouabain	drug	120-126	pentobarbital	drug	257-269	false
ouabain	drug	213-219	ketamine	drug	227-234	false
ouabain	drug	213-219	Innovar	brand	239-245	false
ouabain	drug	213-219	pentobarbital	drug	257-269	false
ketamine	drug	227-234	Innovar	brand	239-245	false
ketamine	drug	227-234	pentobarbital	drug	257-269	false
Innovar	brand	239-245	pentobarbital	drug	257-269	false

DDI-MedLine.d23.s2	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
ouabain	drug	35-41	Innovar	brand	111-117	true
ouabain	drug	35-41	ketamine	drug	120-127	true
ouabain	drug	35-41	droperidol	drug	133-142	true
ouabain	drug	35-41	fentayl	drug	176-182	false
ouabain	drug	35-41	pentobarbital	drug	199-211	false
Innovar	brand	111-117	ketamine	drug	120-127	false
Innovar	brand	111-117	droperidol	drug	133-142	false
Innovar	brand	111-117	fentayl	drug	176-182	false
Innovar	brand	111-117	pentobarbital	drug	199-211	false
ketamine	drug	120-127	droperidol	drug	133-142	false
ketamine	drug	120-127	fentayl	drug	176-182	false
ketamine	drug	120-127	pentobarbital	drug	199-211	false
droperidol	drug	133-142	fentayl	drug	176-182	false
droperidol	drug	133-142	pentobarbital	drug	199-211	false
fentayl	drug	176-182	pentobarbital	drug	199-211	false

DDI-MedLine.d49.s0	Interaction of clindamycin and gentamicin in vitro.
clindamycin	drug	15-25	gentamicin	drug	31-40	true

DDI-MedLine.d49.s1	The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates.
clindamycin	drug	41-51	gentamicin	drug	57-66	false

DDI-MedLine.d49.s3	Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml);
Gentamicin	drug	0-9	clindamycin	drug	50-60	false

DDI-MedLine.d49.s6	Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
clindamycin	drug	16-26	gentamicin	drug	32-41	true

DDI-MedLine.d49.s7	All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml).
clindamycin	drug	155-165	gentamicin	drug	230-239	false

DDI-MedLine.d49.s8	Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
clindamycin	drug	16-26	gentamicin	drug	32-41	true

DDI-MedLine.d120.s0	Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.
amphotericin B	drug	46-59	filipin	drug_n	75-81	false

DDI-MedLine.d120.s1	Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic;
polyene antibiotics	group	10-28	filipin	drug_n	42-48	false

DDI-MedLine.d120.s3	Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;
filipin	drug_n	21-27	amphotericin B	drug	58-71	false
filipin	drug_n	21-27	polyene antibiotics	group	170-188	false
amphotericin B	drug	58-71	polyene antibiotics	group	170-188	false

DDI-MedLine.d120.s4	filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth;
filipin	drug_n	0-6	amphotericin B	drug	65-78	false

DDI-MedLine.d120.s5	and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.
filipin	drug_n	24-30	amphotericin B	drug	151-164	false

DDI-MedLine.d40.s0	Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
miconazole	drug	38-47	miconazole	drug	60-69	false

DDI-MedLine.d40.s1	The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida.
antifungal drug	group	4-18	miconazole nitrate	drug	21-38	false

DDI-MedLine.d29.s0	Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
probenecid	drug	10-19	cloxacillin	drug	79-89	false

DDI-MedLine.d29.s2	(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
penicillins	group	49-59	cephaloridine	drug	65-77	false
penicillins	group	49-59	probenecid	drug	111-120	true
cephaloridine	drug	65-77	probenecid	drug	111-120	true

DDI-MedLine.d29.s3	To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.
probenecid	drug	21-30	cloxacillin	drug	75-85	false
probenecid	drug	21-30	cloxacillin	drug	124-134	false
probenecid	drug	21-30	probenecid	drug	274-283	false
cloxacillin	drug	75-85	cloxacillin	drug	124-134	false
cloxacillin	drug	75-85	probenecid	drug	274-283	false
cloxacillin	drug	124-134	probenecid	drug	274-283	false

DDI-MedLine.d29.s4	No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively).
cloxacillin	drug	93-103	probenecid	drug	122-131	false

DDI-MedLine.d29.s8	This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
probenecid	drug	41-50	cloxacillin	drug	74-84	true

DDI-MedLine.d122.s1	Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products).
alcohol	drug	21-27	nicotine	drug	33-40	false

DDI-MedLine.d122.s3	The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.
alcohol	drug	18-24	nicotine	drug	29-36	false

DDI-MedLine.d122.s4	Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine.
alcohol	drug	85-91	nicotine	drug	97-104	false

DDI-MedLine.d134.s0	[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]
The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied.
radiopertechnetate	drug	50-67	sodium perchlorate	drug_n	72-89	false
radiopertechnetate	drug	50-67	sodium perchlorate	drug_n	170-187	false
radiopertechnetate	drug	50-67	radiopertechnetate	drug	267-284	false
sodium perchlorate	drug_n	72-89	sodium perchlorate	drug_n	170-187	false
sodium perchlorate	drug_n	72-89	radiopertechnetate	drug	267-284	false
sodium perchlorate	drug_n	170-187	radiopertechnetate	drug	267-284	false

DDI-MedLine.d134.s1	An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.
perchlorate	drug_n	29-39	pertechnetate	drug	116-128	false
perchlorate	drug_n	29-39	radiopertechnetate	drug	237-254	false
pertechnetate	drug	116-128	radiopertechnetate	drug	237-254	false

DDI-MedLine.d134.s2	An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
perchlorate	drug_n	28-38	pertechnetate	drug	116-128	true

DDI-MedLine.d118.s0	Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
Sirolimus	drug	0-8	rapamycin	drug	31-39	false

DDI-MedLine.d118.s2	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.
Sirolimus	drug	0-8	immunosuppressants	group	37-54	false
Sirolimus	drug	0-8	sirolimus	drug	148-156	false
Sirolimus	drug	0-8	cyclosporine	drug	231-242	false
Sirolimus	drug	0-8	tacrolimus	drug	247-256	false
immunosuppressants	group	37-54	sirolimus	drug	148-156	false
immunosuppressants	group	37-54	cyclosporine	drug	231-242	false
immunosuppressants	group	37-54	tacrolimus	drug	247-256	false
sirolimus	drug	148-156	cyclosporine	drug	231-242	false
sirolimus	drug	148-156	tacrolimus	drug	247-256	false
cyclosporine	drug	231-242	tacrolimus	drug	247-256	false

DDI-MedLine.d118.s3	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	97-105	cyclosporine	drug	128-139	false
sirolimus	drug	97-105	tacrolimus	drug	144-153	false
sirolimus	drug	97-105	cyclosporine	drug	249-260	false
sirolimus	drug	97-105	tacrolimus	drug	265-274	false
cyclosporine	drug	128-139	tacrolimus	drug	144-153	false
cyclosporine	drug	128-139	cyclosporine	drug	249-260	false
cyclosporine	drug	128-139	tacrolimus	drug	265-274	false
tacrolimus	drug	144-153	cyclosporine	drug	249-260	false
tacrolimus	drug	144-153	tacrolimus	drug	265-274	false
cyclosporine	drug	249-260	tacrolimus	drug	265-274	false

DDI-MedLine.d88.s0	The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
chlordiazepoxide	drug	15-30	amphetamine	drug	33-43	false
chlordiazepoxide	drug	15-30	cocaine	drug	49-55	false
amphetamine	drug	33-43	cocaine	drug	49-55	false

DDI-MedLine.d88.s1	Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in "genetically nervous"
benzodiazepine	group	82-95	chlordiazepoxide	drug	98-113	false

DDI-MedLine.d88.s4	The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects.
cocaine	drug	41-47	amphetamine	drug	52-62	false

DDI-MedLine.d119.s1	Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986.
Fluvastatin	drug	0-10	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	group	25-100	false

DDI-MedLine.d119.s2	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	group	63-89	lovastatin	drug	92-101	false
HMGCoA reductase inhibitors	group	63-89	simvastatin	drug	104-114	false
HMGCoA reductase inhibitors	group	63-89	pravastatin	drug	121-131	false
lovastatin	drug	92-101	simvastatin	drug	104-114	false
lovastatin	drug	92-101	pravastatin	drug	121-131	false
simvastatin	drug	104-114	pravastatin	drug	121-131	false

DDI-MedLine.d119.s15	Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
Cholestyramine	drug	0-13	fluvastatin	drug	103-113	true

DDI-MedLine.d119.s16	Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
cholestyramine	drug	41-54	fluvastatin	drug	83-93	true

DDI-MedLine.d119.s17	Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin.
warfarin	drug	30-37	warfarin	drug	132-139	false
warfarin	drug	30-37	fluvastatin	drug	145-155	false
warfarin	drug	132-139	fluvastatin	drug	145-155	false

DDI-MedLine.d119.s18	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.
niacin	drug	46-51	propranolol	drug	57-67	false
niacin	drug	46-51	fluvastatin	drug	105-115	false
niacin	drug	46-51	digoxin	drug	197-203	false
niacin	drug	46-51	digoxin	drug	267-273	false
propranolol	drug	57-67	fluvastatin	drug	105-115	false
propranolol	drug	57-67	digoxin	drug	197-203	false
propranolol	drug	57-67	digoxin	drug	267-273	false
fluvastatin	drug	105-115	digoxin	drug	197-203	false
fluvastatin	drug	105-115	digoxin	drug	267-273	false
digoxin	drug	197-203	digoxin	drug	267-273	false

DDI-MedLine.d57.s1	The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.
antihistaminics	group	83-97	analgesic agents	group	111-126	false
antihistaminics	group	83-97	analgesic adjuvants	group	141-159	false
analgesic agents	group	111-126	analgesic adjuvants	group	141-159	false

DDI-MedLine.d57.s2	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
diphenhydramine	drug	51-65	hydroxyzine	drug	68-78	false
diphenhydramine	drug	51-65	orphenadrine	drug	81-92	false
diphenhydramine	drug	51-65	pyrilamine	drug	95-104	false
diphenhydramine	drug	51-65	phenyltoloxamine	drug_n	107-122	false
diphenhydramine	drug	51-65	promethazine	drug	125-136	false
diphenhydramine	drug	51-65	methdilazine	drug	139-150	false
diphenhydramine	drug	51-65	tripelennamine	drug	157-170	false
hydroxyzine	drug	68-78	orphenadrine	drug	81-92	false
hydroxyzine	drug	68-78	pyrilamine	drug	95-104	false
hydroxyzine	drug	68-78	phenyltoloxamine	drug_n	107-122	false
hydroxyzine	drug	68-78	promethazine	drug	125-136	false
hydroxyzine	drug	68-78	methdilazine	drug	139-150	false
hydroxyzine	drug	68-78	tripelennamine	drug	157-170	false
orphenadrine	drug	81-92	pyrilamine	drug	95-104	false
orphenadrine	drug	81-92	phenyltoloxamine	drug_n	107-122	false
orphenadrine	drug	81-92	promethazine	drug	125-136	false
orphenadrine	drug	81-92	methdilazine	drug	139-150	false
orphenadrine	drug	81-92	tripelennamine	drug	157-170	false
pyrilamine	drug	95-104	phenyltoloxamine	drug_n	107-122	false
pyrilamine	drug	95-104	promethazine	drug	125-136	false
pyrilamine	drug	95-104	methdilazine	drug	139-150	false
pyrilamine	drug	95-104	tripelennamine	drug	157-170	false
phenyltoloxamine	drug_n	107-122	promethazine	drug	125-136	false
phenyltoloxamine	drug_n	107-122	methdilazine	drug	139-150	false
phenyltoloxamine	drug_n	107-122	tripelennamine	drug	157-170	false
promethazine	drug	125-136	methdilazine	drug	139-150	false
promethazine	drug	125-136	tripelennamine	drug	157-170	false
methdilazine	drug	139-150	tripelennamine	drug	157-170	false

DDI-MedLine.d27.s0	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
picrotoxin	drug_n	117-126	diazepam	drug	174-181	true
picrotoxin	drug_n	117-126	phenazepam	drug_n	184-193	true
picrotoxin	drug_n	117-126	phenibut	drug_n	196-203	true
picrotoxin	drug_n	117-126	amizyl	drug_n	209-214	true
picrotoxin	drug_n	117-126	phentolamine	drug	242-253	true
diazepam	drug	174-181	phenazepam	drug_n	184-193	false
diazepam	drug	174-181	phenibut	drug_n	196-203	false
diazepam	drug	174-181	amizyl	drug_n	209-214	false
diazepam	drug	174-181	phentolamine	drug	242-253	false
phenazepam	drug_n	184-193	phenibut	drug_n	196-203	false
phenazepam	drug_n	184-193	amizyl	drug_n	209-214	false
phenazepam	drug_n	184-193	phentolamine	drug	242-253	false
phenibut	drug_n	196-203	amizyl	drug_n	209-214	false
phenibut	drug_n	196-203	phentolamine	drug	242-253	false
amizyl	drug_n	209-214	phentolamine	drug	242-253	false

DDI-MedLine.d15.s0	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	75-89	false
cerulein	drug_n	16-23	neuroleptics	group	137-148	false
cerulein	drug_n	16-23	haloperidol	drug	269-279	false
cerulein	drug_n	16-23	pyreneperone	drug_n	298-309	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	368-382	false
cerulein	drug_n	16-23	apomorphine	drug	419-429	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	466-480	false
cerulein	drug_n	16-23	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	75-89	neuroleptics	group	137-148	false
3H-spiroperidol	drug_n	75-89	haloperidol	drug	269-279	false
3H-spiroperidol	drug_n	75-89	pyreneperone	drug_n	298-309	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	368-382	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	527-537	false
neuroleptics	group	137-148	haloperidol	drug	269-279	false
neuroleptics	group	137-148	pyreneperone	drug_n	298-309	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	368-382	false
neuroleptics	group	137-148	apomorphine	drug	419-429	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	466-480	false
neuroleptics	group	137-148	apomorphine	drug	527-537	false
haloperidol	drug	269-279	pyreneperone	drug_n	298-309	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	368-382	false
haloperidol	drug	269-279	apomorphine	drug	419-429	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	466-480	false
haloperidol	drug	269-279	apomorphine	drug	527-537	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	368-382	false
pyreneperone	drug_n	298-309	apomorphine	drug	419-429	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	466-480	false
pyreneperone	drug_n	298-309	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	368-382	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	527-537	false
apomorphine	drug	419-429	3H-spiroperidol	drug_n	466-480	false
apomorphine	drug	419-429	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	466-480	apomorphine	drug	527-537	false

DDI-MedLine.d15.s1	After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
neuroleptics	group	34-45	cerulein	drug_n	72-79	false
neuroleptics	group	34-45	3H-spiroperidol	drug_n	164-178	false
cerulein	drug_n	72-79	3H-spiroperidol	drug_n	164-178	false

DDI-MedLine.d15.s2	It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
3H-spiroperidol	drug_n	49-63	apomorphine	drug	101-111	false
3H-spiroperidol	drug_n	49-63	neuroleptics	group	190-201	false
apomorphine	drug	101-111	neuroleptics	group	190-201	false

DDI-MedLine.d56.s0	Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.
ouabain	drug	15-21	palytoxin	drug_n	30-38	false

DDI-MedLine.d56.s1	Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
Palytoxin	drug_n	0-8	PTX	drug_n	11-13	false

DDI-MedLine.d56.s2	In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
ouabain	drug	19-25	PTX	drug_n	39-41	true

DDI-MedLine.d56.s5	When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
ouabain	drug	5-11	phentolamine	drug	58-69	true
ouabain	drug	5-11	PTX	drug_n	119-121	false
phentolamine	drug	58-69	PTX	drug_n	119-121	false

DDI-MedLine.d56.s8	Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
ouabain	drug	26-32	PTX	drug_n	68-70	true

DDI-MedLine.d56.s10	The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain.
ouabain	drug	93-99	ouabain	drug	299-305	false

DDI-MedLine.d139.s0	[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports.
neuroleptics	group	50-61	neuroleptics	group	173-184	false

DDI-MedLine.d82.s1	The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
arsenate	drug_n	29-36	As(V)	drug_n	38-42	false

DDI-MedLine.d82.s2	By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
arsenate	drug_n	40-47	As(V)	drug_n	123-127	false

DDI-MedLine.d82.s4	At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines.
As(V)	drug_n	10-14	As(V)	drug_n	90-94	false

DDI-MedLine.d82.s5	However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V).
As(V)	drug_n	39-43	As(V)	drug_n	137-141	false

DDI-MedLine.d82.s7	Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
arsenate	drug_n	13-20	phosphate	drug	26-34	false

DDI-MedLine.d82.s8	Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
Vitamin D3	drug	0-9	arsenate	drug_n	95-102	true

DDI-MedLine.d22.s2	By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone.
spermidine	drug_n	13-22	putrescine	drug_n	35-44	false

DDI-MedLine.d22.s3	Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
Spermine	drug	0-7	spermidine	drug_n	34-43	false

DDI-MedLine.d100.s5	Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	0-28	verapamil	drug	39-47	false
Slow-channel calcium blockers	group	0-28	diltiazem	drug	50-58	false
Slow-channel calcium blockers	group	0-28	nifedipine	drug	64-73	false
verapamil	drug	39-47	diltiazem	drug	50-58	false
verapamil	drug	39-47	nifedipine	drug	64-73	false
diltiazem	drug	50-58	nifedipine	drug	64-73	false

DDI-MedLine.d63.s0	Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
naloxone	drug	36-43	beta-endorphin	drug_n	111-124	false
naloxone	drug	36-43	morphine	drug	130-137	false
beta-endorphin	drug_n	111-124	morphine	drug	130-137	false

DDI-MedLine.d63.s2	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
naloxone	drug	64-71	beta-endorphin	drug_n	144-157	false
naloxone	drug	64-71	morphine	drug	163-170	false
beta-endorphin	drug_n	144-157	morphine	drug	163-170	false

DDI-MedLine.d63.s3	Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
beta-endorphin	drug_n	30-43	morphine	drug	49-56	false

DDI-MedLine.d63.s4	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
naloxone	drug	25-32	beta-endorphin	drug_n	184-197	true
naloxone	drug	25-32	naloxone	drug	219-226	false
naloxone	drug	25-32	beta-endorphin	drug_n	317-330	false
beta-endorphin	drug_n	184-197	naloxone	drug	219-226	false
beta-endorphin	drug_n	184-197	beta-endorphin	drug_n	317-330	false
naloxone	drug	219-226	beta-endorphin	drug_n	317-330	true

DDI-MedLine.d63.s5	On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
naloxone	drug	31-38	morphine	drug	145-152	true

DDI-MedLine.d63.s6	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
naloxone	drug	30-37	beta-endorphin	drug_n	173-186	true
naloxone	drug	30-37	morphine	drug	192-199	true
beta-endorphin	drug_n	173-186	morphine	drug	192-199	false

DDI-MedLine.d63.s7	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	35-42	beta-endorphin	drug_n	109-122	false
naloxone	drug	35-42	morphine	drug	132-139	false
naloxone	drug	35-42	beta-endorphin	drug_n	206-219	false
naloxone	drug	35-42	morphine	drug	225-232	false
beta-endorphin	drug_n	109-122	morphine	drug	132-139	false
beta-endorphin	drug_n	109-122	beta-endorphin	drug_n	206-219	false
beta-endorphin	drug_n	109-122	morphine	drug	225-232	false
morphine	drug	132-139	beta-endorphin	drug_n	206-219	false
morphine	drug	132-139	morphine	drug	225-232	false
beta-endorphin	drug_n	206-219	morphine	drug	225-232	false

DDI-MedLine.d63.s8	descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
beta-endorphin	drug_n	38-51	morphine	drug	57-64	false

DDI-MedLine.d73.s0	Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	MPTP	drug_n	98-101	false
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	methamphetamine	drug	108-122	false
MPTP	drug_n	98-101	methamphetamine	drug	108-122	false

DDI-MedLine.d73.s1	The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
MPTP	drug_n	56-59	methamphetamine	drug	144-158	false

DDI-MedLine.d73.s2	It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
MPTP	drug_n	21-24	pargyline	drug	143-151	true

DDI-MedLine.d73.s3	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
MPTP	drug	4-7	amphetamine	drug	83-93	true
MPTP	drug	4-7	apomorphine	drug	147-157	true
amphetamine	drug	83-93	apomorphine	drug	147-157	false

DDI-MedLine.d73.s4	Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
Methamphetamine	drug	0-14	MPTP	drug_n	22-25	false
Methamphetamine	drug	0-14	pargyline	drug	107-115	true
MPTP	drug_n	22-25	pargyline	drug	107-115	false

DDI-MedLine.d12.s0	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
Dexamethasone	drug	0-12	retinyl acetate	drug	18-32	false
Dexamethasone	drug	0-12	EGF	drug_n	66-68	true
Dexamethasone	drug	0-12	insulin	drug	74-80	true
retinyl acetate	drug	18-32	EGF	drug_n	66-68	true
retinyl acetate	drug	18-32	insulin	drug	74-80	true
EGF	drug_n	66-68	insulin	drug	74-80	false

DDI-MedLine.d12.s1	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	drug_n	101-111	EGF	drug_n	131-133	false
transferrin	drug_n	101-111	insulin	drug	151-157	false
EGF	drug_n	131-133	insulin	drug	151-157	false

DDI-MedLine.d12.s2	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
dexamethasone	drug	17-29	retinyl acetate	drug	35-49	false
dexamethasone	drug	17-29	transferrin	drug_n	125-135	false
dexamethasone	drug	17-29	EGF	drug_n	180-182	true
dexamethasone	drug	17-29	insulin	drug	188-194	true
retinyl acetate	drug	35-49	transferrin	drug_n	125-135	false
retinyl acetate	drug	35-49	EGF	drug_n	180-182	true
retinyl acetate	drug	35-49	insulin	drug	188-194	true
transferrin	drug_n	125-135	EGF	drug_n	180-182	false
transferrin	drug_n	125-135	insulin	drug	188-194	false
EGF	drug_n	180-182	insulin	drug	188-194	false

DDI-MedLine.d12.s3	Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
Dexamethasone	drug	0-12	retinyl acetate	drug	30-44	false
Dexamethasone	drug	0-12	EGF	drug_n	105-107	true
retinyl acetate	drug	30-44	EGF	drug_n	105-107	true

DDI-MedLine.d12.s4	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
dexamethasone	drug	25-37	retinyl acetate	drug	62-76	false
dexamethasone	drug	25-37	EGF	drug_n	136-138	true
retinyl acetate	drug	62-76	EGF	drug_n	136-138	true

DDI-MedLine.d12.s5	Dexamethasone had a similar effect in the presence of insulin.
Dexamethasone	drug	0-12	insulin	drug	54-60	false

DDI-MedLine.d12.s6	However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
retinyl acetate	drug	9-23	insulin	drug	105-111	true

DDI-MedLine.d12.s7	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
dexamethasone	drug	32-44	retinyl acetate	drug	50-64	false
dexamethasone	drug	32-44	glucocorticoids	group	86-100	false
dexamethasone	drug	32-44	retinoids	group	106-114	false
dexamethasone	drug	32-44	insulin	drug	223-229	true
dexamethasone	drug	32-44	EGF	drug_n	235-237	true
retinyl acetate	drug	50-64	glucocorticoids	group	86-100	false
retinyl acetate	drug	50-64	retinoids	group	106-114	false
retinyl acetate	drug	50-64	insulin	drug	223-229	true
retinyl acetate	drug	50-64	EGF	drug_n	235-237	true
glucocorticoids	group	86-100	retinoids	group	106-114	false
glucocorticoids	group	86-100	insulin	drug	223-229	true
glucocorticoids	group	86-100	EGF	drug_n	235-237	true
retinoids	group	106-114	insulin	drug	223-229	true
retinoids	group	106-114	EGF	drug_n	235-237	true
insulin	drug	223-229	EGF	drug_n	235-237	false

DDI-MedLine.d9.s3	For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	8-36	verapamil	drug	74-82	false
calcium-entry blocking agents	group	8-36	nifedipine	drug	85-94	false
calcium-entry blocking agents	group	8-36	diltiazem	drug	100-108	false
verapamil	drug	74-82	nifedipine	drug	85-94	false
verapamil	drug	74-82	diltiazem	drug	100-108	false
nifedipine	drug	85-94	diltiazem	drug	100-108	false

DDI-MedLine.d9.s5	by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	drug	45-53	diltiazem	drug	59-67	false
verapamil	drug	45-53	nifedipine	drug	87-96	false
diltiazem	drug	59-67	nifedipine	drug	87-96	false

DDI-MedLine.d45.s0	Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d45.s1	The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine
pentazocine	drug	68-78	tripelennamine	drug	84-97	false

DDI-MedLine.d45.s5	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
heroin	drug_n	74-79	pentazocine	drug	93-103	false
heroin	drug_n	74-79	tripelennamine	drug	109-122	false
pentazocine	drug	93-103	tripelennamine	drug	109-122	true

DDI-MedLine.d45.s6	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
tripelennamine	drug	105-118	pentazocine	drug	200-210	true

DDI-MedLine.d45.s9	aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d61.s0	Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
digoxin	drug	34-40	amiodarone	drug	42-51	false

DDI-MedLine.d61.s1	Amiodarone is known to raise serum digoxin levels.
Amiodarone	drug	0-9	digoxin	drug	35-41	true

DDI-MedLine.d61.s3	The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.
digoxin	drug	34-40	digoxin	drug	93-99	false
digoxin	drug	34-40	amiodarone	drug	140-149	false
digoxin	drug	93-99	amiodarone	drug	140-149	false

DDI-MedLine.d61.s4	During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
amiodarone	drug	7-16	digoxin	drug	56-62	true

DDI-MedLine.d61.s8	Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics.
Amiodarone	drug	0-9	digoxin	drug	172-178	false

DDI-MedLine.d61.s9	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
digoxin	drug	21-27	amiodarone	drug	58-67	true
digoxin	drug	21-27	digoxin	drug	99-105	false
amiodarone	drug	58-67	digoxin	drug	99-105	false

DDI-MedLine.d85.s0	Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Misonidazole	drug_n	0-11	CCNU	drug	80-83	true

DDI-MedLine.d85.s1	Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
nitrosourea	group	12-22	CCNU	drug	24-27	false
nitrosourea	group	12-22	CCNU	drug	184-187	false
nitrosourea	group	12-22	misonidazole	drug_n	246-257	false
CCNU	drug	24-27	CCNU	drug	184-187	false
CCNU	drug	24-27	misonidazole	drug_n	246-257	false
CCNU	drug	184-187	misonidazole	drug_n	246-257	false

DDI-MedLine.d85.s7	Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
Misonidazole	drug_n	0-11	CCNU	drug	53-56	true

DDI-MedLine.d85.s9	Misonidazole has a complex effect on oral CCNU pharmacokinetics.
Misonidazole	drug_n	0-11	CCNU	drug	42-45	true

DDI-MedLine.d85.s14	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
CCNU	drug	98-101	misonidazole	drug_n	119-130	true

DDI-MedLine.d7.s0	Enhanced theophylline clearance secondary to phenytoin therapy.
theophylline	drug	9-20	phenytoin	drug	45-53	true

DDI-MedLine.d7.s1	This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
theophylline	drug	41-52	phenytoin	drug	102-110	true

DDI-MedLine.d7.s4	With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
phenytoin	drug	52-60	theophylline	drug	157-168	true

DDI-MedLine.d30.s1	The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	47-66	NANM	drug_n	69-72	false
N-allylnormetazocine	drug_n	47-66	phencyclidine	drug_n	103-115	false
N-allylnormetazocine	drug_n	47-66	PCP	drug_n	118-120	false
NANM	drug_n	69-72	phencyclidine	drug_n	103-115	false
NANM	drug_n	69-72	PCP	drug_n	118-120	false
phencyclidine	drug_n	103-115	PCP	drug_n	118-120	false

DDI-MedLine.d30.s2	Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
(+)-NANM	drug_n	22-29	PCP	drug_n	34-36	false

DDI-MedLine.d30.s6	In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	57-64	false
(-)-NANM	drug_n	12-19	(-)-NANM	drug_n	111-118	false
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	146-153	false
(+)-NANM	drug_n	57-64	(-)-NANM	drug_n	111-118	false
(+)-NANM	drug_n	57-64	(+)-NANM	drug_n	146-153	false
(-)-NANM	drug_n	111-118	(+)-NANM	drug_n	146-153	false

DDI-MedLine.d30.s7	In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
(-)-NANM	drug_n	17-24	(+)-NANM	drug_n	35-42	false
(-)-NANM	drug_n	17-24	morphine	drug	88-95	true
(+)-NANM	drug_n	35-42	morphine	drug	88-95	false

DDI-MedLine.d30.s8	In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
(-)-NANM	drug_n	27-34	(+)-NANM	drug_n	45-52	false
(-)-NANM	drug_n	27-34	PCP	drug_n	57-59	false
(-)-NANM	drug_n	27-34	naloxone	drug	82-89	true
(+)-NANM	drug_n	45-52	PCP	drug_n	57-59	false
(+)-NANM	drug_n	45-52	naloxone	drug	82-89	false
PCP	drug_n	57-59	naloxone	drug	82-89	false

DDI-MedLine.d30.s9	the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
naloxone	drug	13-20	(-)-NANM	drug_n	60-67	true
naloxone	drug	13-20	morphine	drug	150-157	true
(-)-NANM	drug_n	60-67	morphine	drug	150-157	false

DDI-MedLine.d30.s10	In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP.
naloxone	drug	12-19	(-)-NANM	drug_n	65-72	false
naloxone	drug	12-19	(+)-NANM	drug_n	75-82	false
naloxone	drug	12-19	PCP	drug_n	87-89	false
(-)-NANM	drug_n	65-72	(+)-NANM	drug_n	75-82	false
(-)-NANM	drug_n	65-72	PCP	drug_n	87-89	false
(+)-NANM	drug_n	75-82	PCP	drug_n	87-89	false

DDI-MedLine.d30.s11	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
Haloperidol	drug	0-10	(+)-NANM	drug_n	106-113	true
Haloperidol	drug	0-10	PCP	drug_n	118-120	true
Haloperidol	drug	0-10	NANM	drug_n	250-253	false
(+)-NANM	drug_n	106-113	PCP	drug_n	118-120	false
(+)-NANM	drug_n	106-113	NANM	drug_n	250-253	false
PCP	drug_n	118-120	NANM	drug_n	250-253	false

DDI-MedLine.d55.s0	Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
acetaminophen	drug	28-40	caffeine	drug	75-82	true

DDI-MedLine.d55.s1	Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
caffeine	drug	6-13	acetaminophen	drug	50-62	false
caffeine	drug	6-13	caffeine	drug	115-122	false
caffeine	drug	6-13	acetaminophen	drug	149-161	false
acetaminophen	drug	50-62	caffeine	drug	115-122	false
acetaminophen	drug	50-62	acetaminophen	drug	149-161	false
caffeine	drug	115-122	acetaminophen	drug	149-161	false

DDI-MedLine.d55.s4	Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
acetaminophen	drug	58-70	caffeine	drug	91-98	true

DDI-MedLine.d130.s0	High-dose cisplatin with sodium thiosulfate protection.
cisplatin	drug	10-18	sodium thiosulfate	drug	25-42	true

DDI-MedLine.d130.s2	Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
Sodium thiosulfate	drug	0-17	cisplatin	drug	47-55	true

DDI-MedLine.d130.s3	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.
thiosulfate	drug	34-44	cisplatin	drug	75-83	false
thiosulfate	drug	34-44	thiosulfate	drug	130-140	false
thiosulfate	drug	34-44	cisplatin	drug	221-229	false
cisplatin	drug	75-83	thiosulfate	drug	130-140	false
cisplatin	drug	75-83	cisplatin	drug	221-229	false
thiosulfate	drug	130-140	cisplatin	drug	221-229	false

DDI-MedLine.d130.s4	Cisplatin was administered over the last two hours of the thiosulfate infusion.
Cisplatin	drug	0-8	thiosulfate	drug	58-68	false

DDI-MedLine.d130.s6	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.
cisplatin	drug	14-22	thiosulfate	drug	83-93	false
cisplatin	drug	14-22	thiosulfate	drug	147-157	false
cisplatin	drug	14-22	cisplatin	drug	281-289	false
thiosulfate	drug	83-93	thiosulfate	drug	147-157	false
thiosulfate	drug	83-93	cisplatin	drug	281-289	false
thiosulfate	drug	147-157	cisplatin	drug	281-289	false

DDI-MedLine.d130.s8	This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
thiosulfate	drug	58-68	cisplatin	drug	136-144	true

DDI-MedLine.d5.s0	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
coumaphos	drug_n	32-40	coumaphos	drug_n	68-76	false
coumaphos	drug_n	32-40	bishydroxycoumarin	drug	83-100	false
coumaphos	drug_n	32-40	trichlorfon	drug_n	103-113	false
coumaphos	drug_n	32-40	phenobarbital sodium	drug	120-139	false
coumaphos	drug_n	68-76	bishydroxycoumarin	drug	83-100	false
coumaphos	drug_n	68-76	trichlorfon	drug_n	103-113	false
coumaphos	drug_n	68-76	phenobarbital sodium	drug	120-139	false
bishydroxycoumarin	drug	83-100	trichlorfon	drug_n	103-113	false
bishydroxycoumarin	drug	83-100	phenobarbital sodium	drug	120-139	false
trichlorfon	drug_n	103-113	phenobarbital sodium	drug	120-139	false

DDI-MedLine.d5.s1	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	37-45	bishydroxycoumarin	drug	48-65	false
coumaphos	drug_n	37-45	anticoagulant	group	71-83	false
coumaphos	drug_n	37-45	trichlorfon	drug_n	87-97	false
coumaphos	drug_n	37-45	organophosphorous compound	group	103-128	false
coumaphos	drug_n	37-45	phenobarbital sodium	drug	136-155	false
bishydroxycoumarin	drug	48-65	anticoagulant	group	71-83	false
bishydroxycoumarin	drug	48-65	trichlorfon	drug_n	87-97	false
bishydroxycoumarin	drug	48-65	organophosphorous compound	group	103-128	false
bishydroxycoumarin	drug	48-65	phenobarbital sodium	drug	136-155	false
anticoagulant	group	71-83	trichlorfon	drug_n	87-97	false
anticoagulant	group	71-83	organophosphorous compound	group	103-128	false
anticoagulant	group	71-83	phenobarbital sodium	drug	136-155	false
trichlorfon	drug_n	87-97	organophosphorous compound	group	103-128	false
trichlorfon	drug_n	87-97	phenobarbital sodium	drug	136-155	false
organophosphorous compound	group	103-128	phenobarbital sodium	drug	136-155	false

DDI-MedLine.d5.s2	A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
coumaphos	drug_n	24-32	bishydroxy-coumarin	drug	134-152	false

DDI-MedLine.d5.s3	The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
trichlorfon	drug_n	60-70	coumaphos	drug_n	267-275	true

DDI-MedLine.d5.s4	In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
phenobarbital sodium	drug	23-42	coumaphos	drug_n	123-131	true

DDI-MedLine.d2.s0	Failure of neomycin to modify ACTH induced hypertension in sheep.
neomycin	drug	11-18	ACTH	group	30-33	false

DDI-MedLine.d2.s1	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
neomycin	drug	32-39	adrenocortical steroid	group	84-105	false
neomycin	drug	32-39	ACTH	drug	141-144	true
adrenocortical steroid	group	84-105	ACTH	drug	141-144	false

DDI-MedLine.d2.s2	The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
neomycin	drug	20-27	ACTH	group	32-35	false

DDI-MedLine.d2.s3	Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
Neomycin	drug	0-7	ACTH	group	71-74	false

DDI-MedLine.d66.s0	Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.
synthetic steroidal estrogen	group	42-69	synthetic steroidal progestogen	group	42-60;75-85	false

DDI-MedLine.d66.s1	The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine.
ethynyl estradiol	drug	53-69	levonorgestrel	drug	75-88	false

DDI-MedLine.d66.s2	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol.
levonorgestrel	drug	149-162	ethynyl estradiol	drug	219-235	false

DDI-MedLine.d93.s4	Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
trimethyl lead	drug_n	109-122	TML	drug_n	125-127	false

DDI-MedLine.d93.s6	The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol.
alcohol	drug	24-30	ethanol	drug	83-89	false

DDI-MedLine.d93.s9	These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
lead	drug_n	53-56	alcohol	drug	129-135	true

DDI-MedLine.d54.s2	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol.
alcohol	drug	151-157	alcohol	drug	228-234	false

DDI-MedLine.d54.s3	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.
ethanol	drug	110-116	physostigmine	drug	130-142	false
ethanol	drug	110-116	atropine	drug	159-166	false
physostigmine	drug	130-142	atropine	drug	159-166	false

DDI-MedLine.d54.s8	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
Physostigmine	drug	0-12	alcohol	drug	62-68	true
Physostigmine	drug	0-12	alcohol	drug	123-129	true
alcohol	drug	62-68	alcohol	drug	123-129	false

DDI-MedLine.d54.s10	Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2.
Atropine	drug	0-7	alcohol	drug	46-52	false

DDI-MedLine.d81.s0	Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
disulfiram	drug	31-40	ethanol	drug	42-48	false

DDI-MedLine.d81.s1	Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER).
disulfiram	drug	88-97	ethanol	drug	99-105	false

DDI-MedLine.d81.s2	Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
ethanol	drug	71-77	disulfiram	drug	117-126	true
ethanol	drug	71-77	ethanol	drug	147-153	false
disulfiram	drug	117-126	ethanol	drug	147-153	false

DDI-MedLine.d81.s3	The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol.
ethanol	drug	58-64	ethanol	drug	142-148	false

DDI-MedLine.d81.s6	Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol.
ethanol	drug	47-53	ethanol	drug	97-103	false

DDI-MedLine.d131.s0	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
neurotensin	drug_n	50-60	enkephalins	drug_n	66-76	true
neurotensin	drug_n	50-60	tuftsin	drug_n	81-87	true
enkephalins	drug_n	66-76	tuftsin	drug_n	81-87	false

DDI-MedLine.d131.s1	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	59-69	enkephalins	drug_n	80-90	false
neurotensin	drug_n	59-69	D-Ala2-metenkephalinamide	drug_n	118-142	false
neurotensin	drug_n	59-69	tuftsin	drug_n	148-154	false
enkephalins	drug_n	80-90	D-Ala2-metenkephalinamide	drug_n	118-142	false
enkephalins	drug_n	80-90	tuftsin	drug_n	148-154	false
D-Ala2-metenkephalinamide	drug_n	118-142	tuftsin	drug_n	148-154	false

DDI-MedLine.d131.s3	It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
neurotensin	drug_n	18-28	enkephalins	drug_n	82-92	true

DDI-MedLine.d131.s4	On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
neurotensin	drug_n	17-27	tuftsin	drug_n	33-39	true

DDI-MedLine.d131.s5	It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
neurotensin	drug_n	21-31	tuftsin	drug_n	132-138	true

DDI-MedLine.d97.s8	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
thiabendazole	drug	92-104	melarsoprol	drug	143-153	true

DDI-MedLine.d97.s10	Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.
anti-helminthic	group	59-73	melarsoprol	drug	171-181	false

DDI-MedLine.d34.s0	Interactions of cobalt and iron in absorption and retention.
cobalt	drug	16-21	iron	drug	27-30	true

DDI-MedLine.d34.s1	The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
cobalt	drug	34-39	iron	drug	45-48	false
cobalt	drug	34-39	Co	drug	271-272	false
cobalt	drug	34-39	Fe	drug	297-298	false
iron	drug	45-48	Co	drug	271-272	false
iron	drug	45-48	Fe	drug	297-298	false
Co	drug	271-272	Fe	drug	297-298	false

DDI-MedLine.d34.s4	Cobalt excretion was enhanced by supplementary cobalt;
Cobalt	drug	0-5	cobalt	drug	47-52	false

DDI-MedLine.d34.s7	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
iron	drug	11-14	cobalt	drug	58-63	true
iron	drug	11-14	cobalt	drug	81-86	true
cobalt	drug	58-63	cobalt	drug	81-86	false

DDI-MedLine.d34.s8	The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
Fe	drug	60-61	Fe	drug	83-84	false
Fe	drug	60-61	cobalt	drug	141-146	true
Fe	drug	83-84	cobalt	drug	141-146	false

DDI-MedLine.d34.s9	Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
iron	drug	28-31	cobalt	drug	53-58	true

DDI-MedLine.d34.s11	Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred.
cobalt	drug	27-32	iron	drug	67-70	false
cobalt	drug	27-32	cobalt	drug	108-113	false
cobalt	drug	27-32	iron	drug	118-121	false
iron	drug	67-70	cobalt	drug	108-113	false
iron	drug	67-70	iron	drug	118-121	false
cobalt	drug	108-113	iron	drug	118-121	false

DDI-MedLine.d34.s12	Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)
iron	drug	15-18	Fe	drug	189-190	false

DDI-MedLine.d39.s0	Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.
estradiol	drug	10-18	endotoxin	drug_n	23-31	false

DDI-MedLine.d39.s1	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
estradiol	drug	36-44	endotoxin	drug_n	141-149	false
estradiol	drug	36-44	endotoxin	drug_n	216-224	false
endotoxin	drug_n	141-149	endotoxin	drug_n	216-224	false

DDI-MedLine.d39.s2	Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
estradiol	drug	13-21	endotoxin	drug_n	56-64	true
estradiol	drug	13-21	endotoxin	drug_n	129-137	false
endotoxin	drug_n	56-64	endotoxin	drug_n	129-137	false

DDI-MedLine.d39.s3	The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
estradiol	drug	37-45	endotoxin	drug_n	49-57	true
estradiol	drug	37-45	endotoxin	drug_n	109-117	false
endotoxin	drug_n	49-57	endotoxin	drug_n	109-117	false

DDI-MedLine.d39.s4	The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
estradiol	drug	37-45	endotoxin	drug_n	49-57	false
estradiol	drug	37-45	endotoxin	drug_n	117-125	false
endotoxin	drug_n	49-57	endotoxin	drug_n	117-125	false

DDI-MedLine.d39.s6	Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
estradiol	drug	10-18	endotoxin	drug_n	65-73	true

DDI-MedLine.d39.s8	These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
estrogen	group	61-68	estrogens	group	108-116	false

DDI-MedLine.d128.s1	The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
16,16-dimethylprostaglandin E2	drug_n	4-33	dmPGE2	drug_n	36-41	false

DDI-MedLine.d128.s10	On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.
dmPGE2	drug_n	62-67	dmPGE2	drug_n	179-184	false

DDI-MedLine.d128.s12	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.)
Loperamide	drug	0-9	morphine	drug	15-22	false

DDI-MedLine.d128.s13	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
Loperamide	drug	0-9	morphine	drug	15-22	false
Loperamide	drug	0-9	dmPGE2	drug_n	64-69	true
morphine	drug	15-22	dmPGE2	drug_n	64-69	true

DDI-MedLine.d128.s15	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
N-methyllevallorphan	drug_n	0-19	loperamide	drug	85-94	true
N-methyllevallorphan	drug_n	0-19	morphine	drug	133-140	true
loperamide	drug	85-94	morphine	drug	133-140	false

DDI-MedLine.d89.s0	Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
99mTc-methylene diphosphonate	drug	71-99	gentamicin	drug	107-116	true

DDI-MedLine.d89.s1	Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
Gentamicin	drug	0-9	aminoglycoside antibiotic	group	17-41	false

DDI-MedLine.d89.s2	Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
gentamicin	drug	27-36	99mTc-MDP	drug	84-92	true

DDI-MedLine.d89.s7	Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients.
gentamicin	drug	37-46	99mTc-MDP	drug	89-97	false
gentamicin	drug	37-46	radiopharmaceutical	group	106-124	false
99mTc-MDP	drug	89-97	radiopharmaceutical	group	106-124	false

DDI-MedLine.d89.s8	The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.
gentamicin	drug	79-88	gentamicin	drug	127-136	false

DDI-MedLine.d11.s4	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	41-63	corticosteroids	group	74-88	false
immunosuppressive drugs	group	41-63	cyclosporin	drug	91-101	false
immunosuppressive drugs	group	41-63	azathioprine	drug	104-115	false
immunosuppressive drugs	group	41-63	methotrexate	drug	118-129	false
immunosuppressive drugs	group	41-63	cyclophosphamide	drug	132-147	false
corticosteroids	group	74-88	cyclosporin	drug	91-101	false
corticosteroids	group	74-88	azathioprine	drug	104-115	false
corticosteroids	group	74-88	methotrexate	drug	118-129	false
corticosteroids	group	74-88	cyclophosphamide	drug	132-147	false
cyclosporin	drug	91-101	azathioprine	drug	104-115	false
cyclosporin	drug	91-101	methotrexate	drug	118-129	false
cyclosporin	drug	91-101	cyclophosphamide	drug	132-147	false
azathioprine	drug	104-115	methotrexate	drug	118-129	false
azathioprine	drug	104-115	cyclophosphamide	drug	132-147	false
methotrexate	drug	118-129	cyclophosphamide	drug	132-147	false

DDI-MedLine.d107.s1	Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.
ethanol	drug	98-104	acetaldehyde	drug_n	129-140	false

DDI-MedLine.d107.s3	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	111-117	methanol	drug_n	120-127	false
ethanol	drug	111-117	alcohols	drug_n	137-144	false
ethanol	drug	111-117	acetaldehyde	drug_n	150-161	false
methanol	drug_n	120-127	alcohols	drug_n	137-144	false
methanol	drug_n	120-127	acetaldehyde	drug_n	150-161	false
alcohols	drug_n	137-144	acetaldehyde	drug_n	150-161	false

DDI-MedLine.d107.s9	These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
ethanol	drug	47-53	acetaldehyde	drug_n	128-139	true

DDI-MedLine.d53.s0	Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
vitamin D	group	61-69	antiestrogens	group	75-87	false

DDI-MedLine.d53.s1	1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	drug	2-31	1,25(OH)2D3	drug	34-44	false
25-Dihydroxycholecalciferol D3	drug	2-31	vitamin D	group	73-81	false
1,25(OH)2D3	drug	34-44	vitamin D	group	73-81	false

DDI-MedLine.d53.s3	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	71-81	antiestrogen	group	91-102	false
1,25(OH)2D3	drug	71-81	4-hydroxytamoxifen	drug_n	104-121	false
1,25(OH)2D3	drug	71-81	TAM	drug_n	124-126	false
antiestrogen	group	91-102	4-hydroxytamoxifen	drug_n	104-121	false
antiestrogen	group	91-102	TAM	drug_n	124-126	false
4-hydroxytamoxifen	drug_n	104-121	TAM	drug_n	124-126	false

DDI-MedLine.d53.s4	Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
TAM	drug_n	22-24	1,25(OH)2D3	drug	92-102	true

DDI-MedLine.d53.s5	Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
1,25(OH)2D3	drug	24-34	TAM	drug_n	40-42	true

DDI-MedLine.d53.s9	These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.
vitamin-D	group	90-98	estrogen	group	137-144	false

DDI-MedLine.d51.s1	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
caffeine	drug	63-70	theophylline	drug	73-84	false
caffeine	drug	63-70	8-phenyltheophylline	drug_n	87-106	false
caffeine	drug	63-70	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
caffeine	drug	63-70	DPCPX	drug_n	149-153	false
theophylline	drug	73-84	8-phenyltheophylline	drug_n	87-106	false
theophylline	drug	73-84	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
theophylline	drug	73-84	DPCPX	drug_n	149-153	false
8-phenyltheophylline	drug_n	87-106	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
8-phenyltheophylline	drug_n	87-106	DPCPX	drug_n	149-153	false
8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	DPCPX	drug_n	149-153	false

DDI-MedLine.d51.s3	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
theophylline	drug	26-37	CGS 21680	drug_n	73-81	true
theophylline	drug	26-37	N6-cyclopentyladenosine	drug_n	120-142	false
theophylline	drug	26-37	CPA	drug_n	145-147	false
CGS 21680	drug_n	73-81	N6-cyclopentyladenosine	drug_n	120-142	false
CGS 21680	drug_n	73-81	CPA	drug_n	145-147	false
N6-cyclopentyladenosine	drug_n	120-142	CPA	drug_n	145-147	false

DDI-MedLine.d51.s4	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
theophylline	drug	31-42	CGS21680	drug_n	74-81	true
theophylline	drug	31-42	DPCPX	drug_n	142-146	false
theophylline	drug	31-42	CGS 21680	drug	200-208	false
theophylline	drug	31-42	CPA	drug_n	217-219	false
CGS21680	drug_n	74-81	DPCPX	drug_n	142-146	false
CGS21680	drug_n	74-81	CGS 21680	drug	200-208	false
CGS21680	drug_n	74-81	CPA	drug_n	217-219	false
DPCPX	drug_n	142-146	CGS 21680	drug	200-208	false
DPCPX	drug_n	142-146	CPA	drug_n	217-219	false
CGS 21680	drug	200-208	CPA	drug_n	217-219	false

DDI-MedLine.d4.s0	[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied.
sandimmune	brand	15-24	immunodepressant	group	119-134	false
sandimmune	brand	15-24	sandimmune	brand	146-155	false
immunodepressant	group	119-134	sandimmune	brand	146-155	false

DDI-MedLine.d68.s0	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs]
The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
cimetidine	drug	15-24	verografin	drug	52-61	false
cimetidine	drug	15-24	iodamide	drug	67-74	false
cimetidine	drug	15-24	cimetidine	drug	115-124	false
cimetidine	drug	15-24	verografine	drug	157-167	false
cimetidine	drug	15-24	iodamide	drug	173-180	false
verografin	drug	52-61	iodamide	drug	67-74	false
verografin	drug	52-61	cimetidine	drug	115-124	false
verografin	drug	52-61	verografine	drug	157-167	false
verografin	drug	52-61	iodamide	drug	173-180	false
iodamide	drug	67-74	cimetidine	drug	115-124	false
iodamide	drug	67-74	verografine	drug	157-167	false
iodamide	drug	67-74	iodamide	drug	173-180	false
cimetidine	drug	115-124	verografine	drug	157-167	true
cimetidine	drug	115-124	iodamide	drug	173-180	true
verografine	drug	157-167	iodamide	drug	173-180	false

DDI-MedLine.d68.s1	The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
verografine	drug	11-21	iodamide	drug	27-34	false

DDI-MedLine.d68.s2	In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport.
cimetidine	drug	9-18	cardiotrast	drug	47-57	false

DDI-MedLine.d68.s3	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
cimetidine	drug	44-53	verografine	drug	58-68	false
cimetidine	drug	44-53	iodamide	drug	74-81	false
verografine	drug	58-68	iodamide	drug	74-81	false

DDI-MedLine.d103.s1	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
magnesium	drug	36-44	magnesium	drug	75-83	false
magnesium	drug	36-44	magnesium	drug	144-152	false
magnesium	drug	36-44	magnesium	drug	193-201	false
magnesium	drug	36-44	magnesium	drug	230-238	false
magnesium	drug	36-44	magnesium	drug	302-310	false
magnesium	drug	75-83	magnesium	drug	144-152	false
magnesium	drug	75-83	magnesium	drug	193-201	false
magnesium	drug	75-83	magnesium	drug	230-238	false
magnesium	drug	75-83	magnesium	drug	302-310	false
magnesium	drug	144-152	magnesium	drug	193-201	false
magnesium	drug	144-152	magnesium	drug	230-238	false
magnesium	drug	144-152	magnesium	drug	302-310	false
magnesium	drug	193-201	magnesium	drug	230-238	false
magnesium	drug	193-201	magnesium	drug	302-310	false
magnesium	drug	230-238	magnesium	drug	302-310	false

DDI-MedLine.d103.s2	Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy.
magnesium	drug	22-30	magnesium	drug	98-106	false

DDI-MedLine.d103.s3	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
magnesium	drug	94-102	magnesium	drug	140-148	false
magnesium	drug	94-102	magnesium	drug	184-192	false
magnesium	drug	94-102	magnesium	drug	260-268	false
magnesium	drug	94-102	magnesium	drug	336-344	false
magnesium	drug	140-148	magnesium	drug	184-192	false
magnesium	drug	140-148	magnesium	drug	260-268	false
magnesium	drug	140-148	magnesium	drug	336-344	false
magnesium	drug	184-192	magnesium	drug	260-268	false
magnesium	drug	184-192	magnesium	drug	336-344	false
magnesium	drug	260-268	magnesium	drug	336-344	false

DDI-MedLine.d103.s4	Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment.
magnesium	drug	19-27	magnesium	drug	77-85	false

DDI-MedLine.d103.s5	Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure.
magnesium	drug	19-27	magnesium salt	drug	110-123	false

DDI-MedLine.d103.s6	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.
magnesium	drug	37-45	magnesium sparing diuretics	group	86-112	false
magnesium	drug	37-45	vitamin B6	drug	140-149	false
magnesium	drug	37-45	vitamin D	group	175-183	false
magnesium	drug	37-45	selenium	drug	192-199	false
magnesium sparing diuretics	group	86-112	vitamin B6	drug	140-149	false
magnesium sparing diuretics	group	86-112	vitamin D	group	175-183	false
magnesium sparing diuretics	group	86-112	selenium	drug	192-199	false
vitamin B6	drug	140-149	vitamin D	group	175-183	false
vitamin B6	drug	140-149	selenium	drug	192-199	false
vitamin D	group	175-183	selenium	drug	192-199	false

DDI-MedLine.d103.s8	There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).
magnesium	drug	79-87	magnesium	drug	155-163	false

DDI-MedLine.d103.s15	Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.
magnesium	drug	71-79	cardioplegic solutions	drug	100-121	false

DDI-MedLine.d20.s0	Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
glycine	drug	20-26	glutamate	drug	32-40	true

DDI-MedLine.d20.s4	The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
glycine	drug	30-36	glutamate	drug	75-83	true
glycine	drug	30-36	glutamate	drug	246-254	false
glutamate	drug	75-83	glutamate	drug	246-254	false

DDI-MedLine.d94.s11	The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
isoproterenol	drug	20-32	norepinephrine	drug	64-77	false

DDI-MedLine.d94.s12	The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
cocaine	drug	22-28	desipramine	drug	34-44	false
cocaine	drug	22-28	norepinephrine	drug	108-121	true
desipramine	drug	34-44	norepinephrine	drug	108-121	true

DDI-MedLine.d94.s13	Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
mazindol	drug	70-77	norepinephrine	drug	135-148	false

DDI-MedLine.d94.s16	This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only.
cocaine	drug	99-105	desipramine	drug	111-121	false

DDI-MedLine.d94.s17	Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
norepinephrine	drug	12-25	cocaine	drug	90-96	false
norepinephrine	drug	12-25	desipramine	drug	102-112	false
cocaine	drug	90-96	desipramine	drug	102-112	false

DDI-MedLine.d14.s0	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion.
angiotensin	drug_n	45-55	angiotensin 1	drug_n	184-196	false
angiotensin	drug_n	45-55	angiotensin 2	drug_n	202-214	false
angiotensin	drug_n	45-55	pentagastrin	drug	219-230	false
angiotensin	drug_n	45-55	histamine	drug	237-245	false
angiotensin 1	drug_n	184-196	angiotensin 2	drug_n	202-214	false
angiotensin 1	drug_n	184-196	pentagastrin	drug	219-230	false
angiotensin 1	drug_n	184-196	histamine	drug	237-245	false
angiotensin 2	drug_n	202-214	pentagastrin	drug	219-230	false
angiotensin 2	drug_n	202-214	histamine	drug	237-245	false
pentagastrin	drug	219-230	histamine	drug	237-245	false

DDI-MedLine.d14.s1	It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine.
pentagastrin	drug	89-100	histamine	drug	113-121	false

DDI-MedLine.d14.s2	Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.
angiotensins	drug_n	127-138	angiotensin	drug_n	167-177	false

DDI-MedLine.d90.s0	Interaction of gentamycin and atracurium in anaesthetised horses.
gentamycin	drug	15-24	atracurium	drug	30-39	true

DDI-MedLine.d90.s1	Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane.
atracurium	drug	101-110	halothane	drug	152-160	false

DDI-MedLine.d90.s3	Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v.
Atracurium	drug	0-9	gentamycin	drug	91-100	false

DDI-MedLine.d90.s7	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
atracurium	drug	65-74	atracurium	drug	107-116	false
atracurium	drug	65-74	gentamycin	drug	123-132	false
atracurium	drug	107-116	gentamycin	drug	123-132	true

DDI-MedLine.d90.s8	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
atracurium	drug	72-81	atracurium	drug	114-123	false
atracurium	drug	72-81	gentamycin	drug	130-139	false
atracurium	drug	114-123	gentamycin	drug	130-139	true

DDI-MedLine.d90.s9	At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
atracurium	drug	55-64	atracurium	drug	90-99	false
atracurium	drug	55-64	gentamycin	drug	106-115	false
atracurium	drug	90-99	gentamycin	drug	106-115	true

DDI-MedLine.d90.s11	It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
gentamycin	drug	32-41	atracurium	drug	85-94	true

DDI-MedLine.d113.s0	Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
temazepam	drug	30-38	ethanol	drug	65-71	true

DDI-MedLine.d113.s1	The benzodiazepines are a family of anxiolytic and hypnotic drugs.
benzodiazepines	group	4-18	anxiolytic	group	36-45	false
benzodiazepines	group	4-18	hypnotic drugs	group	51-64	false
anxiolytic	group	36-45	hypnotic drugs	group	51-64	false

DDI-MedLine.d113.s3	In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
temazepam	drug	105-113	benzodiazepine	group	118-131	false
temazepam	drug	105-113	ethanol	drug	138-144	true
benzodiazepine	group	118-131	ethanol	drug	138-144	false

DDI-MedLine.d113.s5	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
alcohol	drug	111-117	3-hydroxy-1,4-benzodiazepine	group	123-150	true

